

FINANCIAL INFORMATION

The following discussion and analysis of our Group's financial condition and results of operations in conjunction with our Group's combined financial information included in the Accountants' Report, which has been prepared in accordance with HKFRSs, as set out in Appendix I to this prospectus, and the pro forma financial information included in Appendix II to this prospectus, in each case together with the accompanying notes.

The following discussion and analysis contains certain forward-looking statements that reflect our current views with respect to future events and financial performance. These statements are based on our assumptions and analysis in light of our experience and perception of historical trends, current conditions and expected future developments, as well as factors that we believe are appropriate under the circumstances. However, our Group's actual results and timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the section headed "Risk factors" and elsewhere in this prospectus.

OVERVIEW

We are an established pharmaceutical distributor originated from Zhejiang province and headquartered in Hangzhou, Zhejiang province. We are principally engaged in pharmaceutical distribution businesses in the PRC. We start involving our pharmaceutical distribution business from the stage of acquiring the distribution rights of pharmaceutical products from our suppliers, market research and market development of our new products, assisting and co-ordinating the provincial collective tendering process for our suppliers, procurement, sourcing, sales and marketing, warehousing and delivery to our Distributor Customers. We source and procure our products from the pharmaceutical manufacturers and pharmaceutical companies throughout different provinces in the PRC, and distribute pharmaceutical products to our Distributor Customers. A majority of our products will in turn be distributed through our Distributor Customers to the ultimate customers which mainly comprise hospitals and medical institutions in the PRC in accordance with the geographical exclusivity of our products.

Our success relies on identification and procurement of pharmaceutical products nationwide in the PRC and the establishment of our efficient distribution network. As at the Latest Practicable Date, we sourced and procured our pharmaceutical products through our network of 47 suppliers in the PRC, and sold all of our pharmaceutical products through our distribution network of 117 Distributor Customers in 19 provinces throughout the PRC. As at the Latest Practicable Date, 42 out of 117 Distributor Customers were located in Zhejiang province while the remaining 75 Distributor Customers were spread over 18 regions in the PRC including Shanghai, Hainan province, Jiangxi province and Guangdong province. Our Distributor Customers distribute and resell our products to their sub-distributors and/or ultimate customers. For each of the two years ended 31 December 2011 and 2012 and the six months ended 30 June 2013, the revenue generated from our top five Distributor Customers amounted to approximately HK\$93.2 million, HK\$121.4 million and HK\$59.3 million, respectively, representing approximately 58.4%, 69.4% and 70.9% of our total revenue during the corresponding periods.

FINANCIAL INFORMATION

Our revenue for each of the two years ended 31 December 2011 and 2012 was approximately HK\$159,686,000 and HK\$175,042,000, respectively, representing a growth of approximately 9.6%. Our revenue for the six months ended 30 June 2012 and 2013 was approximately HK\$89,828,000 and HK\$83,672,000, respectively, representing a decrease of approximately 6.9%. Our gross profit for each of the two years ended 31 December 2011 and 2012 was approximately HK\$23,286,000 and HK\$38,993,000, respectively, representing a growth of approximately 67.5%. Our gross profit for the six months ended 30 June 2012 and 2013 was approximately HK\$20,717,000 and HK\$18,455,000, respectively, representing a decrease of approximately 10.9%. Our profit for each of the two years ended 31 December 2011 and 2012 was approximately HK\$10,412,000 and HK\$15,327,000, respectively, representing a growth of approximately 47.2%. Our profit for the six months ended 30 June 2012 and 2013 was approximately HK\$11,491,000 and HK\$1,530,000, respectively, representing a decrease of approximately 86.7%.

REORGANISATION AND BASIS OF PRESENTATION

Our Company was incorporated on 9 August 2012 in Bermuda and, as part of the Reorganisation became the holding company of our Group with our business being conducted through our subsidiaries. Please refer to the section headed “History and Development – Reorganisation” of this prospectus for details.

The financial information presents our combined results and financial position as if the current group structure had been in existence through the Track Record Period. All material intra-group transactions and balances have been eliminated on combination.

SIGNIFICANT FACTORS AFFECTING RESULTS OF OPERATIONS AND FINANCIAL CONDITION

The major factors affecting the results of operations and financial condition of our Group at any given time included the following:

Demand for pharmaceutical products and policies of the PRC government

Our results of operations are significantly affected by the demand for pharmaceutical products in the PRC, which is in turn influenced by various factors, such as PRC government policy and changes in the PRC healthcare industry. This market is driven by the growing PRC economy, the high urbanisation growth, the increasing health consciousness and the rising disposable incomes. The growth of the healthcare industry in China significantly contributed to an increase in demand for our products and thus a growth in our business during the Track Record Period.

The demand for pharmaceutical products will continue to be influenced by government policy. The sales amount of pharmaceutical products listed in the Medical Insurance Drug Catalogs would be significantly higher than those not listed in that catalog. Therefore, whether the pharmaceutical products that our Group has the exclusive distribution rights are included in the Medical Insurance Drug Catalogs can affect our business significantly. However, the pharmaceutical products included in the Medical Insurance Drugs Catalogs are subject to government price controls in the form

FINANCIAL INFORMATION

of fixed retail prices or retail price ceilings and periodic downward adjustments in pricing. The PRC government may further lower the retail price ceilings of pharmaceutical products from time to time to make healthcare more affordable to the public. Regulatory controls over and downward adjustments to retail prices of pharmaceutical products, if significant, could have an adverse impact on the revenue of the Group.

Product Combination

During the Track Record Period, we acquired exclusive distribution rights of various products and recorded different gross profit margins for different products. Also, market potential varies from product to product depending on the market conditions, competitive landscape, the nature of manufacturers and product natures. Our profitability and results of operation therefore varied significantly from period to period as a result of changes in the combination of products sold during the relevant period.

Procurement of pharmaceutical products

Our ability to maintain and increase turnover is significantly affected by our supply chain. During the Track Record Period, we were able to secure our major products and acquired 7 new types of products (including 9 specifications) with exclusive distribution rights and 1 new product with a legally binding contract already entered to our product portfolio in order to maintain a stable level of turnover.

According to applicable PRC laws and regulations, the procurement of substantially all pharmaceutical products, including the pharmaceutical products listed in the Medical Insurance Drugs Catalogs, is subject to a provincial collective tendering process through which only successful bidders may sell their products to public hospitals and other public healthcare institutions. Therefore, assisting our suppliers to participate and win the provincial collective tendering process is one of the crucial elements to our business. If our suppliers fail to win the provincial collective tendering process, our revenue associated with the sales of the pharmaceutical products involved in the provincial collective tendering process to the hospitals in the relevant regions and also our results of operations may be adversely affected. The failure of securing our existing major products may also adversely affect our results of operation.

Distribution network coverage and scale of operations

Our established distribution network, particularly in Zhejiang province, allows us to distribute products to our ultimate customers including hospitals and medical institutions in an effective and efficient manner. Our strong network of Distribution Customers, and the network of medical institutions and practitioners in Zhejiang province, and the scale of our operations provide us with competitive advantages over our competitors.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The discussion and analysis of our operating results and financial position are based on our combined financial information, together with the notes thereto, included in the Accountants' Report set out in Appendix I to this prospectus. Preparation of our financial statements requires us to make estimates and judgments in applying our critical accounting policies with a significant impact on the results that we report in our financial statements. Some of our accounting policies involve subjective assumptions and estimates, as well as complex judgments relating to accounting items. Estimates and judgments are from time to time evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Our operating results and financial position are sensitive to the accounting methods, assumptions and estimates that underlie the preparation of the financial information. Actual results may differ from these estimates under different assumptions and conditions. We believe that the following accounting policies involve the most significant judgments and estimates used in the preparation of our financial statements. For more details about our significant accounting policies, please refer to Note 4 of the Accountants' Report as disclosed in Appendix I to this prospectus.

Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods sold and services provided in the normal course of business, net of discounts and sales related taxes.

Revenue from sales of goods is recognised when goods are delivered and titles are passed at the time when all the following conditions are satisfied:

- our Group has transferred to the buyer the significant risks and rewards of ownership of the goods;
- our Group retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the Group; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Specifically, we recognise our revenue when the products are delivered at the warehouses of the Distributor Customers or the designated pick-up area as instructed by the Distributor Customers. From that point of time, the related risks are transferred to the Distributor Customers.

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to our Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and the effective interest rate applicable, being the rate that discounts the estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

FINANCIAL INFORMATION

Inventories

Inventories are stated at the lower of cost and net reliable value. Cost is calculated using the weighted average method. Net realisable value represents the estimated selling price for inventories less all estimated costs of completion and costs necessary to the sale.

Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the financial information because it excludes items of income or expenses that are taxable or deductible in other years and further excludes items that are never taxable or deductible. Our Group's liabilities for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the financial information and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

Deferred tax liabilities are recognised for taxable temporary differences associated with investments in subsidiaries, except where our Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments and interests are only recognised to the extent that it is probable that there will be sufficient taxable profit against which to utilise the benefits of the temporary differences and they are expected to reverse in the foreseeable future.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the assets to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realised, based on tax rate (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which our Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

FINANCIAL INFORMATION

Current and deferred tax are recognised in profit or loss, except when it relates to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax are also recognised in other comprehensive income or directly in equity, respectively. Where current tax or deferred tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination.

DESCRIPTION OF PRINCIPAL ITEMS OF RESULTS OF OPERATIONS

Revenue

Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods sold and services provided in the normal course of business, net of discounts and sales related taxes. During the Track Record Period, the turnover was derived from the sales of our pharmaceutical products. The following table sets forth a breakdown of turnover by product type for the Track Record Period:

	Year ended 31 December				Six months ended 30 June			
	2011		2012		2012		2013	
	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total
	HK\$'000	(%)	HK\$'000	(%)	HK\$'000	(%)	HK\$'000	(%)
Revenue								
Injection drugs	137,691	86.2	151,242	86.4	77,929	86.8	70,586	84.4
Tablet drugs	10,243	6.4	14,501	8.3	7,733	8.6	6,256	7.5
Capsule drugs	10,032	6.3	6,636	3.8	2,380	2.6	4,355	5.2
Other drugs	1,720	1.1	2,663	1.5	1,786	2.0	2,475	2.9
Total	<u>159,686</u>	<u>100.0</u>	<u>175,042</u>	<u>100.0</u>	<u>89,828</u>	<u>100.0</u>	<u>83,672</u>	<u>100.0</u>

Injection drugs sales generated a predominant portion of our revenue and accounted for approximately 86.2%, 86.4% and 84.4% of our total revenue for each of the two years ended 31 December 2011 and 2012 and the six months ended 30 June 2013, respectively.

Our revenue had increased by approximately 9.6% for the year ended 31 December 2012, and had decreased by approximately 6.9% for the six months ended 30 June 2013.

FINANCIAL INFORMATION

The following table sets forth a breakdown of turnover by our 11 major types of products (including 17 specifications) for the Track Record Period:

	Year ended 31 December		2012		Six months ended 30 June		2013	
	Amount	% of	Amount	% of	Amount	% of	Amount	% of
	HK\$'000	total	HK\$'000	total	HK\$'000	total	HK\$'000	total
		(%)		(%)	(Unaudited)	(%)		(%)
Revenue								
Levocarnitine Injection (左卡尼汀注射液)	20,072	12.6	52,227	29.8	27,105	30.2	28,271	33.8
Ozagrel Sodium for Injection (注射用奧紮格雷鈉)	12,730	8.0	10,419	6.0	8,858	9.9	81	0.1
Cefoxitin Sodium for Injection (注射用頭孢西丁鈉)	6,590	4.1	6,378	3.6	3,663	4.1	160	0.2
Cefodizime Sodium for Injection (注射用頭孢地嗪鈉)	12,760	8.0	18,287	10.4	9,492	10.6	6,854	8.2
Thymosin α 1 for injection (注射用胸腺法新)	9,410	5.9	12,872	7.4	5,318	5.9	8,173	9.8
Isepamicin Sulfate Injection (硫酸異帕米星注射液)	13,136	8.2	10,015	5.7	4,566	5.1	5,698	6.8
Cefixime Dispersible Tablet (頭孢克肟分散片)	7,848	4.9	6,808	3.9	3,866	4.3	2,212	2.6
Alanyl Glutamine for Injection (注射用丙氨酰谷氨酰胺)	4,580	2.9	9,217	5.3	4,454	5.0	4,319	5.2
Ceftizoxime Sodium for Injection (注射用頭孢唑肟鈉)	3,744	2.3	6,901	3.9	3,032	3.4	3,669	4.4
Sulbenicillin Sodium for Injection (注射用磺苄西林鈉)	10,394	6.5	642	0.4	150	0.2	4,012	4.8
Clostridium butyricum Capsule (酪酸梭菌活菌膠囊)	-	-	1,678	1.0	19	0.0	2,860	3.4
Others	58,422	36.6	39,598	22.6	19,305	21.3	17,363	20.7
Total	159,686	100.0	175,042	100.0	89,828	100.0	83,672	100.0

Note: Each product included in "Others" contributed less than 3% of the revenue for each of the two years ended 31 December 2011 and 2012 and the six months ended 30 June 2013, respectively.

(i) *For the year ended 31 December 2012*

The increase in sales amount of Levocarnitine Injection (左卡尼汀注射液) was primarily attributable to the increased sales volume since medical practitioners had gradually become more familiar with the product after it was listed in the Medical Insurance Drugs Catalogs in 2009 and effective from 31 March 2010. For the year ended 31 December 2012, the sales volume of Levocarnitine Injection (左卡尼汀注射液) increased by approximately 161.2% as compared to the year ended 31 December 2011. The number of covered hospitals increased from 41 in 2011 to 60 in 2012. The increase in sales amount of Cefodizime Sodium for Injection (注射用頭孢地嗪鈉) was primarily attributable to the increase in demand from hospitals. For the year ended 31 December 2012, the sales volume of Cefodizime Sodium for Injection (注射用頭孢地嗪鈉) increased by approximately 37.6% as compared to the year ended 31 December 2011.

FINANCIAL INFORMATION

The increase in sales amount of Ceftizoxime Sodium for Injection (注射用頭孢唑肟鈉) was primarily attributable to the increased hospital coverage in 2012. For the year ended 31 December 2012, the sales volume of Ceftizoxime Sodium for Injection (注射用頭孢唑肟鈉) increased by approximately 64.7% as compared to the year ended 31 December 2011.

The decrease in sales amount of Ozagrel Sodium for Injection (注射用奧紮格雷鈉) was primarily attributable to the price control to lower the retail price of this product on 21 March 2012 and 8 October 2012 imposed by Zhejiang Provincial Price Bureau and NDRC respectively. The decrease in sales amount of Isepamicin Sulfate Injection (硫酸異帕米星注射液) was primarily attributable to a decline in demand from hospitals as a result of the insurance of the Administrative Catalogue of the Clinical Use of Antibiotics of Zhejiang Province (2012 version) (浙江省抗菌藥物臨床應用分級管理目錄(2012版)), which restricted the usage of certain antibiotics. Isepamicin Sulfate Injection (硫酸異帕米星注射液) was one of the antibiotics categorized as limited use listed in such medical catalog. The decrease in sales amount of Sulbencillin Sodium for Injection (注射用磺苄西林鈉) was mainly due to the shortage of its supply as a result of the revised GMP standards and the resumption of the supply of such product since October 2012.

The sales amounts of Cefoxitin Sodium for Injection (注射用頭孢西丁鈉) and Cefixime Dispersible Tablet (頭孢克肟分散片) were generally stable for the year ended 31 December 2012.

The decrease in the sales amount of “Others” was mainly attributable to the supply shortage of Cefotaxime Sodium and Sulbactam Sodium for Injection 2.25g (注射用頭孢噻肟鈉舒巴坦鈉2.25g) and Cefotaxime Sodium and Sulbactam Sodium for Injection 1.5g (注射用頭孢噻肟鈉舒巴坦鈉1.5g). The decrease in sales amount of Cefotaxime Sodium and Sulbactam Sodium for Injection 2.25g (注射用頭孢噻肟鈉舒巴坦鈉) was approximately HK\$3,712,000. This was mainly due to the shortage of its supply as a result of delay in the upgrade of its production facilities to meet the revised GMP standards after we returned a batch of such products to Kaihongxin given the expiry date of such batch of products falling within less than one year which violated our quality control policy. For the year ended 31 December 2012, the decrease in sales amount of Cefotaxime Sodium and Sulbactam Sodium for Injection 1.5g (注射用頭孢噻肟鈉舒巴坦鈉1.5g) was approximately HK\$6,099,000. This was mainly due to our failure to renew the contract with the supplier due to the shareholding changes of that supplier.

FINANCIAL INFORMATION

(ii) *For the six months ended 30 June 2013*

The decrease in sales amount of Ozagrel Sodium for Injection (注射用奧紮格雷鈉) was primarily due to our cessation in sales of Ozagrel Sodium for Injection (注射用奧紮格雷鈉) of 20mg specification in October 2012 as it became no longer profitable for us to continue its sales after several times of price controls. We have put less marketing effort for Ozagrel Sodium for Injection (注射用奧紮格雷鈉) of 80mg specification and 40mg specification as the profitability was limited after several times of price controls which lowered the retail prices of such products and we have ceased the sales of 80mg specification and 40mg specification of this product in June 2013. The decrease in sales amount of Cefoxitin Sodium for Injection (注射用頭孢西丁鈉) was primarily due to such product having fallen within the category of limited use under the Administrative Catalogue of the Clinical Use of Antibiotics of Zhejiang Province (2012 version) (浙江省抗菌藥物臨床應用分級管理目錄(2012版)) which affected its sales performance. Therefore, we did not renew the distribution agreement with the supplier of one of the specifications of such product, namely Cefoxitin Sodium for Injection 0.5g (注射用頭孢西丁鈉0.5g) after the expiration of the distribution agreement on 30 December 2012. The decrease in sales amount of Cefodizime Sodium for Injection (注射用頭孢地嗪鈉) and Cefixime Dispersible Tablet (頭孢克肅分散片) was primarily due to such products having fallen within the category of limited use under the Administrative Catalogue of the Clinical Use of Antibiotics of Zhejiang Province (2012 version) (浙江省抗菌藥物臨床應用分級管理目錄(2012版)) which was effective from July 2012 and affected their sales performance.

The increase in sales amounts of Thymosin α 1 for Injection (注射用胸腺法新) and Isepamicin Sulfate Injection (硫酸異帕米星注射液) was primarily due to the increased hospital coverage for the six months ended 30 June 2013 with an increase in the average monthly sales amount. The increase in sales amount of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) was primarily due to the resumption of the supply of such product from Type 1 Supplier A since October 2012. The increase in sales amount of Clostridium butyricum Capsule (酪酸梭菌活菌膠囊) of approximately HK\$2,841,000 was due to our entering into the distribution agreement with the supplier in relation to this product on 25 September 2012, which only recorded sales for three months in 2012.

The sales amount of (i) Levocarnitine Injection (左卡尼汀注射液); (ii) Alanyl Glutamine for Injection (注射用丙氨酰谷氨酰胺); and (iii) Ceftizoxime Sodium for Injection (注射用頭孢唑肅鈉) was generally stable for the six months ended 30 June 2013.

FINANCIAL INFORMATION

Cost of sales

Cost of sales represents cost directly attributed to our revenue generating activities. Our Group's cost of sales mainly comprises cost of purchasing merchandise. Our Group was not engaged in pharmaceutical manufacturing business during the Track Record Period. Our cost of sales does not include the selling and distribution expenses. The following table sets forth a breakdown of cost of sales by product type for the Track Record Period:

	Year ended 31 December				Six months ended 30 June			
	2011		2012		2012		2013	
	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total
	HK\$'000	(%)	HK\$'000	(%)	HK\$'000	(%)	HK\$'000	(%)
	(Unaudited)							
Cost of sales								
Injection drugs	119,283	87.5	118,340	87.0	60,052	86.9	55,946	85.8
Tablet drugs	7,699	5.6	11,142	8.2	5,735	8.3	5,018	7.7
Capsule drugs	7,741	5.7	3,967	2.9	1,638	2.4	1,920	2.9
Other drugs	1,677	1.2	2,600	1.9	1,686	2.4	2,333	3.6
Total	136,400	100.0	136,049	100.0	69,111	100.0	65,217	100.0

The amount of our cost of sales had been stable for each of the two years ended 31 December 2011 and 2012. However, for the year ended 31 December 2012, cost of sales represented a decrease of approximately 0.3%, while our revenue represented an increase of approximately 9.6%. For the six months ended 30 June 2013, cost of sales represented a decrease of approximately 5.6%, while our revenue represented a decrease of approximately 6.9%.

Gross Profit

Gross profit represents the difference of turnover and cost of sales. The table below sets forth our gross profit and gross profit margin by product type for the Track Record Period:

	Year ended 31 December				Six months ended 30 June			
	2011		2012		2012		2013	
	Gross Profit		Gross Profit		Gross Profit		Gross Profit	
	Amount	Margin	Amount	Margin	Amount	Margin	Amount	Margin
	HK\$'000	(%)	HK\$'000	(%)	HK\$'000	(%)	HK\$'000	(%)
	(Unaudited)							
Gross Profit								
Injection drugs	18,408	13.4	32,902	21.8	17,877	22.9	14,640	20.7
Tablet drugs	2,544	24.8	3,359	23.2	1,998	25.8	1,238	19.8
Capsule drugs	2,291	22.8	2,669	40.2	742	31.2	2,435	55.9
Other drugs	43	2.5	63	2.4	100	5.6	142	5.7
Total	23,286	14.6	38,993	22.3	20,717	23.1	18,455	22.1

FINANCIAL INFORMATION

(i) *For the year ended 31 December 2012*

The gross profit margin increased from approximately 14.6% for the year ended 31 December 2011 to approximately 22.3% for the year ended 31 December 2012.

The increase in gross profit margin of injection drugs was mainly attributable to that (i) the manufacturers offered us lower prices for certain products, such as Levocarnitine Injection (左卡尼汀注射液), primarily due to higher sales volume we generated for the year ended 31 December 2012. The average unit cost of Levocarnitine Injection (左卡尼汀注射液) decreased by approximately 9.8%, and the sales volume of Levocarnitine Injection (左卡尼汀注射液) increased by approximately 161.2% as compared to the year ended 31 December 2011 that resulted in an increase in the gross profit margin of approximately 6.2%. The sales of Levocarnitine Injection (左卡尼汀注射液) was approximately HK\$20,072,000 and HK\$52,227,000, representing approximately 12.6% and 29.8% of our total revenue for each of two years ended 31 December 2011 and 2012, respectively; (ii) we were able to obtain a product known as Ozagrel Sodium for Injection (注射用奧扎格雷鈉) directly from the manufacturer with lower price without going through the intermediary which was no longer engaged in the business of distributing such type of products in 2012. Hence, we have become the provincial distributor in Zhejiang province for such products and directly sourced such products from the manufacturer. The average unit cost of Ozagrel Sodium for Injection 80mg (注射用奧紮格雷鈉80mg) decreased by approximately 79.8% as compared to the year ended 31 December 2011 that resulted in an increase in the gross profit margin of approximately 73.3%. The sales amount of Ozagrel Sodium for Injection (注射用奧紮格雷鈉) was approximately HK\$12,730,000 and HK\$10,419,000, representing approximately 8.0% and 6.0% of our total revenue for each of two years ended 31 December 2011 and 2012; and (iii) we were able to sell a product known as Mezlocillin Sodium and Sulbactam Sodium for Injection (注射用美洛西林鈉舒巴坦鈉) at a substantially higher price to our Type 1 Distributor Customers with larger sales volume during the year ended 31 December 2012 instead of selling such product to Type 2 Distributor Customers within Zhejiang province. Our Group was responsible for the marketing activities for the year ended 31 December 2012, and was thus able to sell such product to the Type 1 Distributor Customers with a substantially higher price. The average unit selling price of Mezlocillin Sodium and Sulbactam Sodium for Injection (注射用美洛西林鈉舒巴坦鈉) increased by 139.8% as compared to the year ended 31 December 2011 that resulted in an increase in the gross profit margin of approximately 50.6%. The sales amount of Mezlocillin Sodium and Sulbactam Sodium for Injection (注射用美洛西林鈉舒巴坦鈉) was approximately HK\$1,338,000 and HK\$4,223,000, representing approximately 0.8% and 2.4% of our total revenue, respectively.

The increase in gross profit margin of capsule drugs was mainly attributable to the introduction of Clostridium butyricum Capsule (酪酸梭菌活菌膠囊) since September 2012. The sales amount of Clostridium butyricum Capsule (酪酸梭菌活菌膠囊) was approximately HK\$1,679,000 for the year ended 31 December 2012, and the gross profit margin of such product was substantially higher than the average gross profit margin level of capsule drugs for the year ended 31 December 2011. The gross profit margin was stable for tablets drugs and other drugs for the year ended 31 December 2012.

FINANCIAL INFORMATION

(ii) *For the six months ended 30 June 2013*

The gross profit margin was generally stable since 2012, and recorded at 23.1% and 22.1% for the six months ended 30 June 2012 and 2013, respectively.

The decrease in gross profit margin of injection drugs was mainly attributable to the cessation of the sales of Ozagrel Sodium for Injection (注射用奧紮格雷鈉). The gross profit margin of such products was higher than the average gross profit margin of the injection drugs for the six months ended 30 June 2012. Therefore, the substantial decrease in the sales amount of Ozagrel Sodium for Injection (注射用奧紮格雷鈉) for the six months ended 30 June 2013 lowered the gross profit margin of the injection drugs for the same period.

The decrease in gross profit margin of tablet drugs was mainly attributable to the decrease in the sales amount and gross profit margin of Cefixime Dispersible Tablet (頭孢克肅分散片). The sales amount of Cefixime Dispersible Tablet (頭孢克肅分散片) was approximately HK\$3,866,000 and HK\$2,212,000, representing 50.0% and 35.4% of the sales amount of the tablet drugs for the six months ended 30 June 2012 and 2013, respectively. The gross profit margin of such products was higher than the average gross profit margin of the tablet drugs for the six months ended 30 June 2012 and 2013. Therefore, the decrease in the sales amount and gross profit margin of Cefixime Dispersible Tablet (頭孢克肅分散片) for the six months ended 30 June 2013 lowered the gross profit margin of the tablet drugs for the same period.

The increase in gross profit margin of capsule drugs was mainly attributable to the introduction of Clostridium butyricum Capsule (酪酸梭菌活菌膠囊) since September 2012. The sales amount of Clostridium butyricum Capsule (酪酸梭菌活菌膠囊) was approximately HK\$2,860,000 for the six months ended 30 June 2013, representing approximately 65.7% of the sales amount of the capsule drugs and the gross profit margin of such product was substantially higher than the average gross profit margin level of capsule drugs for the six months ended 30 June 2012. The gross profit margin for other drugs was stable for the six months ended 30 June 2013.

Our Directors believe that the Group is well positioned in conducting the business of distribution of pharmaceutical products in Zhejiang province. During the Track Record Period, the market competition and technology improvement did not adversely and materially affected the gross profit margin of the Group.

FINANCIAL INFORMATION

Other income, gains and losses

Other income, gains and losses primarily includes (i) bank interest income; (ii) sundry income; (iii) imputed interest on deposit paid to a supplier, Shenyang Meiluo for each of the two years ended 31 December 2011 and 2012, and Zhongcheng Huida and Kaihongxin for the six months ended 30 June 2013; (iv) impairment loss on amount due from Haikou Xin Lang, a joint venture; and (v) gain on disposal of property, plant and equipment. The following table sets forth a breakdown of other income, gains and losses for the Track Record Period:

	Year ended 31 December		Six months ended 30 June	
	2011	2012	2012	2013
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>
			(Unaudited)	
Bank interest income	299	135	84	150
Sundry income	63	166	–	–
Imputed interest and adjustment on deposit paid to suppliers	397	1,243	212	472
Impairment loss on amount due from a joint venture	(600)	–	–	–
Gain on disposal of property, plant and equipment	–	–	–	428
	<u>–</u>	<u>–</u>	<u>–</u>	<u>428</u>
Total	<u>159</u>	<u>1,544</u>	<u>296</u>	<u>1,050</u>

Pursuant to the tri-partite agreement entered by Shenyang Meiluo, Type 1 Supplier A and our Group in July 2012, Type 1 Supplier A has undertaken to our Group that the deposits and prepayments that originally paid to Shenyang Meiluo from our Group for the supply of the product has been transferred to Type 1 Supplier A as the deposit for supply of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉). Such deposit, which was classified as non-current asset as at 31 December 2011 with the carrying amounts determined based on the present value of future cash flows discounted using an effective interest at 5%, was reclassified as current assets as at 31 December 2012 as this contract expired on 30 June 2013. The adjustment of HK\$1,031,000 was included in imputed interest and adjustment on deposit paid to a supplier. As of 1 January 2013, the amount of RMB7 million and RMB8 million represented deposits paid to Kaihongxin and Zhongcheng Huida, respectively, as securities for purchase of goods from 1 January 2013 to 31 December 2015 as stated in the renewed contracts. However, such deposits of RMB15 million (equivalent to HK\$18,645,000), in aggregate, would not be realised within twelve months from 30 June 2013. Accordingly, the amounts were included in the non-current assets as at 30 June 2013. The carrying amounts as at 30 June 2013 were determined based on the present value of future cash flows discounted using an effective interest rate of 6%. Imputed interest and adjustment of approximately HK\$472,000 was recognised for the six months ended 30 June 2013. A gain of approximately HK\$428,000 was recognised for the disposal of motor vehicles for the six months ended 30 June 2013.

FINANCIAL INFORMATION

Selling and distribution costs

Our selling and distribution expenses principally include (i) salaries; (ii) marketing expenses; (iii) rental expenses; (iv) depreciations of building, plant and equipment, which are primarily for sales and services purposes; (v) travel expenses for our sales team; (vi) transportation cost; and (vii) other miscellaneous selling and distribution expenses.

Our selling and distribution expenses were approximately HK\$2,909,000, HK\$3,112,000 and HK\$1,355,000 for each of the two years ended 31 December 2011 and 2012 and the six months ended 30 June 2013, respectively. The following table sets forth a breakdown of selling and distribution expenses for the Track Record Period:

	Year ended 31 December		Six months ended 30 June	
	2011	2012	2012	2013
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>
			(Unaudited)	
Salaries	1,633	1,558	597	680
Marketing expenses	133	344	115	108
Rental expenses	214	301	147	164
Depreciations	167	154	83	56
Travelling expenses	147	89	50	56
Transportation cost	474	538	207	219
Others	141	128	38	72
	<u>2,909</u>	<u>3,112</u>	<u>1,237</u>	<u>1,355</u>
Total	<u>2,909</u>	<u>3,112</u>	<u>1,237</u>	<u>1,355</u>

Administrative Expenses

Our administrative expenses principally include (i) salaries and benefits for our management and administrative team; (ii) office and rental expenses; (iii) travel and business development expenses; (iv) depreciation and amortisation; (v) other tax expenses; (vi) other miscellaneous administrative expense.

Our administrative expenses were approximately HK\$5,944,000, HK\$6,635,000 and HK\$3,339,000 for each of the two years ended 31 December 2011 and 2012 and the six months ended 30 June 2013, respectively. The following table sets forth a breakdown of administrative expenses for the Track Record Period:

	Year ended 31 December		Six months ended 30 June	
	2011	2012	2012	2013
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>
			(Unaudited)	
Salaries and benefits	2,305	2,215	1,088	1,578
Office and rental expenses	976	1,003	490	477
Travel and business development expenses	381	633	170	117
Depreciation and amortization	1,487	1,479	731	610
Other tax expenses	340	589	156	161
Others	455	716	394	396
	<u>5,944</u>	<u>6,635</u>	<u>3,029</u>	<u>3,339</u>
Total	<u>5,944</u>	<u>6,635</u>	<u>3,029</u>	<u>3,339</u>

FINANCIAL INFORMATION

Listing Expenses

The total costs of the Listing is estimated to be approximately HK\$29.0 million, of which approximately HK\$10.9 million is expected to be capitalised to offset against the share premium accounts in equity after the Listing. The Listing expenses of approximately HK\$8.6 million and HK\$5.4 million was charged to the audited combined statements of profit or loss and other comprehensive income for the year ended 31 December 2012 and the six months ended 30 June 2013, respectively. The additional amount of approximately HK\$4.1 million is expected to be charged to the profit and loss accounts for the year ending 31 December 2013. During the Track Record Period, our Group's Listing expenses of approximately HK\$6.2 million had been paid and deferred to be offset against the share premium account in equity after the Listing, and therefore treated in the prepayment and included in "trade and other receivables" on the combined statement of financial position, and HK\$4.7 million is expected to be capitalised and offset against the share premium account in equity after the Listing.

Our Group financed the payment of the Listing expenses through (i) our internal financial resources; and (ii) the available banking facilities of our Group.

Finance Costs

Our finance costs include interest on amounts due to a related party, bank and other borrowings wholly repayable within one year and imputed interest adjustment as deposit paid to suppliers upon initial recognition. For each of the two years ended 31 December 2011 and 2012 and the six months ended 30 June 2013, our finance costs were approximately HK\$187,000, HK\$38,000 and HK\$3,855,000, respectively. The significant increase for the six months ended 30 June 2013 was primarily due to the imputed interest adjustment on deposits paid to suppliers including Zhongcheng Huida and Kaihongxin to secure their supplies of products from 1 January 2013 to 31 December 2015 as stated in the renewed contracts upon initial recognition of approximately HK\$3,014,000, and the interest on bank and other borrowings wholly repayable within one year arising from the drawdown of the banking facilities of approximately HK\$841,000 for the six months ended 30 June 2013. According to HKAS 32 and 39, the deposit paid to Zhongcheng Huida and Kaihongxin, that are non-current in nature, has to be discounted to its present value. The carrying amounts as at 30 June 2013 are determined based on the present value of future cash flows discounted using an effective interest rate of 6%. The imputed interest adjustment upon initial recognition of approximately HK\$3,014,000 was recognised in the finance costs accordingly.

FINANCIAL INFORMATION

Income tax expense

Income tax expenses represent our total current and deferred tax expenses. During the Track Record Period, income tax expenses consisted entirely of tax expenses incurred by our PRC subsidiaries. Under the Law of the PRC on Enterprise Income Tax (the “EIT Law”) and Implementation Rules to the EIT Law, the tax rate of the PRC subsidiaries has been 25% from 1 January 2008 onwards. No provision was made for profits tax in Hong Kong, Bermuda and BVI as there was no income assessable for tax in these jurisdictions during the Track Record Period. The table below sets forth the reconciliation between tax expenses and accounting profit at the applicable tax rates:

	Year ended 31 December		Six months ended 30 June	
	2011	2012	2012	2013
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>
			(Unaudited)	
Profit before tax	<u>15,258</u>	<u>22,185</u>	<u>16,747</u>	<u>5,538</u>
Tax at the domestic income tax rate of 25%	3,815	5,546	4,188	1,384
Tax effect of share of result of a joint venture	155	–	–	–
Tax effect of income not taxable for tax purpose	(508)	(311)	(64)	(122)
Tax effect of expense not deductible for tax purpose	245	2,296	35	2,237
Tax losses not recognised	82	101	48	66
Deferred tax (reversal of deferred tax) on undistributed earnings of PRC subsidiaries	<u>1,057</u>	<u>(774)</u>	<u>1,049</u>	<u>443</u>
Tax charge for the year/period	<u>4,846</u>	<u>6,858</u>	<u>5,256</u>	<u>4,008</u>
Effective tax rate	<u>31.8%</u>	<u>30.9%</u>	<u>31.4%</u>	<u>72.4%</u>

During the Track Record Period, the effective tax rate was approximately 31.8%, 30.9% and 72.4% for each of the two years ended 31 December 2011 and 2012 and the six months ended 30 June 2013. The increase in the effective tax rate for the six months ended 30 June 2013 was mainly due to the increase in the tax effect of expense not deductible for tax purpose, which was resulted from the payment of the Listing expenses of approximately HK\$5.4 million and the imputed interest adjustment as deposit paid to Zhongcheng Huida and Kaihongxin upon initial recognition of approximately HK\$3.0 million.

The provision of deferred tax on undistributed earnings of PRC subsidiaries is in accordance with Hong Kong Accounting Standard 12.

FINANCIAL INFORMATION

MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE RESULTS OF THE OPERATIONS

The combined statements of profit or loss and other comprehensive income of the Group during the Track Record Period are summarised as below:

	Year ended 31 December		Six months ended 30 June	
	2011 <i>HK\$'000</i>	2012 <i>HK\$'000</i>	2012 <i>HK\$'000</i> (Unaudited)	2013 <i>HK\$'000</i>
Revenue	159,686	175,042	89,828	83,672
Cost of Sales	<u>(136,400)</u>	<u>(136,049)</u>	<u>(69,111)</u>	<u>(65,217)</u>
	23,286	38,993	20,717	18,455
Other income, gains and losses	159	1,544	296	1,050
Selling and distribution expenses	(2,909)	(3,112)	(1,237)	(1,355)
Administrative expenses	(5,944)	(6,635)	(3,029)	(3,339)
Gain on disposal of assets classified as held for sale	1,473	–	–	–
Share of result of a joint venture	(620)	–	–	–
Listing expenses	–	(8,567)	–	(5,418)
Finance costs	<u>(187)</u>	<u>(38)</u>	<u>–</u>	<u>(3,855)</u>
Profit before tax	15,258	22,185	16,747	5,538
Income tax expense	<u>(4,846)</u>	<u>(6,858)</u>	<u>(5,256)</u>	<u>(4,008)</u>
Profit for the year/period	10,412	15,327	11,491	1,530
Other comprehensive income (expense) for the year/period				
<i>Item that will not be reclassified to profit or loss:</i>				
Exchange difference arising on translation of functional currency to presentation currency	4,730	1,143	(1,222)	2,354
Total comprehensive income for the year/period	<u>15,142</u>	<u>16,470</u>	<u>10,269</u>	<u>3,884</u>
Profit for the year/period attributable to owners of the Company	<u>10,412</u>	<u>15,327</u>	<u>11,491</u>	<u>1,530</u>
Total comprehensive income for the year/period attributable to owners of the Company	<u>15,142</u>	<u>16,470</u>	<u>10,269</u>	<u>3,884</u>

FINANCIAL INFORMATION

Year ended 31 December 2012 compared with year ended 31 December 2011

Revenue

The total revenue for the year ended 31 December 2012 was approximately HK\$175,042,000, representing an increase of approximately 9.6% from approximately HK\$159,686,000 for the year ended 31 December 2011. The growth was primarily due to the increase in revenue from Levocarnitine Injection (左卡尼汀注射液) and Cefodizime Sodium for Injection (注射用頭孢地嗪鈉) offset by the decrease in revenue from Ozagrel Sodium for Injection (注射用奧紮格雷鈉) and Isepamicin Sulfate Injection (硫酸異帕米星注射液).

Cost of sales

The cost of sales for the year ended 31 December 2012 was approximately HK\$136,049,000, representing a decrease of approximately 0.3% from approximately HK\$136,400,000 for the year ended 31 December 2011.

Gross Profit

As a result of the foregoing, our gross profit increased by approximately HK\$15,707,000, or approximately 67.5%, from approximately HK\$23,286,000 in 2011 to approximately HK\$38,993,000 in 2012. Our gross profit margin increased from approximately 14.6% in 2011 to approximately 22.3% in 2012, which was mainly attributable to the increase in the gross profit margin of injection drugs and capsule drugs.

Other income, gains and losses

Other income, gains and losses for the year ended 31 December 2012 was approximately HK\$1,544,000, representing an increase of approximately 871.1% from approximately HK\$159,000 for the year ended 31 December 2011. The increase was mainly due to an increase in imputed interest on the deposit paid to Shenyang Meiluo of approximately HK\$846,000.

Selling and distribution expenses

Selling and distribution expenses for the year ended 31 December 2012 was approximately HK\$3,112,000, representing an increase of approximately 7.0% from approximately HK\$2,909,000 for the year ended 31 December 2011. The selling and distribution expenses were generally stable and in line with the change on turnover.

Administrative expenses

Administrative expenses for the year ended 31 December 2012 were approximately HK\$6,635,000, representing an increase of approximately 11.6% from approximately HK\$5,944,000 for the year ended 31 December 2011. The administrative expenses were generally stable and in line with the change on turnover.

Listing expenses

Listing expenses for the year ended 31 December 2012 were approximately HK\$8,567,000.

FINANCIAL INFORMATION

Profit before tax

As a result of the foregoing, profit before tax for the year ended 31 December 2012 was approximately HK\$22,185,000, representing an increase of approximately 45.4% from approximately HK\$15,258,000 for the year ended 31 December 2011. The increase was primarily due to (i) a higher gross profit due to different product mix; and (ii) an increase in imputed interest on the deposit paid to a supplier. The result was partially offset by the Listing expenses incurred during 2012.

Income tax expenses

Income tax expenses for the year ended 31 December 2012 was approximately HK\$6,858,000, representing an increase of approximately 41.5% from approximately HK\$4,846,000 for the year ended 31 December 2011. The increase was primarily due to the higher profit before tax.

Profit for the year

As a result of the foregoing, profit for the year ended 31 December 2012 was approximately HK\$15,327,000, representing an increase of approximately 47.2% from approximately HK\$10,412,000 for the year ended 31 December 2011.

The six months ended 30 June 2013 compared with the six months ended 30 June 2012

Revenue

The total revenue for the six months ended 30 June 2013 was approximately HK\$83,672,000, representing a decrease of approximately 6.9% from approximately HK\$89,828,000 for the six months ended 30 June 2012. The decrease was primarily due to the decrease in sales amount of Ozagrel Sodium for Injection (注射用奧紮格雷鈉) and Cefoxitin Sodium for Injection (注射用頭孢西丁鈉) for the six months ended 30 June 2013.

Cost of sales

The cost of sales for the six months ended 30 June 2013 was approximately HK\$65,217,000, representing a decrease of approximately 5.6% to approximately HK\$69,111,000 for the six months ended 30 June 2012.

Gross Profit

As a result of the foregoing, our gross profit decreased by approximately HK\$2,262,000, or approximately 10.9%, from approximately HK\$20,717,000 for the six months ended 30 June 2012 to approximately HK\$18,455,000 for the six months ended 30 June 2013. Our gross profit margin decreased from approximately 23.1% for the six months ended 30 June 2012 to approximately 22.1% for the six months ended 30 June 2013. Such decrease was mainly attributable to the decrease in the gross profit margin of injection drugs and tablet drugs, and partially offset by the increase in the gross profit margin of capsule drugs.

Other income, gains and losses

Other income, gains and losses for the six months ended 30 June 2013 was approximately HK\$1,050,000, representing an increase of approximately 254.7% from

FINANCIAL INFORMATION

approximately HK\$296,000 for the six months ended 30 June 2012. Such increase was primarily due to (i) an increase in imputed interest on deposits paid to suppliers of approximately HK\$260,000; and (ii) a gain on disposal of motor vehicles of approximately HK\$428,000.

Selling and distribution expenses

Selling and distribution expenses for the six months ended 30 June 2013 was approximately HK\$1,355,000, representing an increase of approximately 9.5% from approximately HK\$1,237,000 for the six months ended 30 June 2012. Such increase was primarily due to the increase in salaries.

Administrative expenses

Administrative expenses for the six months ended 30 June 2013 was approximately HK\$3,339,000, representing an increase of approximately 10.2% to approximately HK\$3,029,000 for the six months ended 30 June 2012. Such increase was mainly due to the increase in salaries and benefits.

Listing expenses

Listing expenses for the six months ended 30 June 2013 was approximately HK\$5,418,000 as compared to nil for the six months ended 30 June 2012.

Finance costs

Finance costs for the six months ended 30 June 2013 was approximately HK\$3,855,000 as compared to nil for the six months ended 30 June 2012. The increase was mainly due to imputed interest adjustment on deposit paid to Zhongcheng Huida and Kaihongxin upon initial recognition of HK\$3,014,000.

Profit before tax

As a result of the foregoing, profit before tax for the six months ended 30 June 2013 was approximately HK\$5,538,000, representing a decrease of approximately 66.9% from approximately HK\$16,747,000 for the six months ended 30 June 2012. The decrease was primarily due to (i) the decrease in gross profit resulted from the decrease in revenue and gross profit margin; (ii) the Listing expenses of approximately HK\$5.4 million; and (iii) the increase in finance costs as a result of the imputed interest adjustment on deposits paid to Zhongcheng Huida and Kaihongxin upon initial recognition of approximately HK\$3.0 million.

Income tax expenses

Income tax expenses for the six months ended 30 June 2013 was approximately HK\$4,008,000, representing a decrease of approximately 23.7% to approximately HK\$5,256,000 for the six months ended 30 June 2012. The decrease was primarily due to the decrease in profit before tax, and partially offset by the increase in the tax effect of expense not deductible for tax purpose resulted from the payment of the Listing expenses and the imputed interest adjustment on deposit paid to suppliers upon initial recognition.

FINANCIAL INFORMATION

Profit for the period

As a result of the foregoing, profit for the six months ended 30 June 2013 was approximately HK\$1,530,000, representing a decrease of approximately 86.7% from approximately HK\$11,491,000 for the six months ended 30 June 2012.

LIQUIDITY AND CAPITAL RESOURCES

Cash Flows

Our primary uses of cash are to pay for purchases of our products from suppliers, and to fund our working capital. We maintain our liquidity through internal resources, banking facilities, and unsecured loan facilities.

In the future, we believe that our liquidity requirements will be satisfied by using combined cash flows generated from our operating activities, banking facilities, unsecured loan facilities, the proceeds from the Placing and other funds raised from capital markets from time to time.

The following table sets forth selected cash flow data from our combined cash flow statements for the Track Record Period:

	Year ended 31 December		Six months ended 30 June	
	2011	2012	2012	2013
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>
			(Unaudited)	
Cash and cash equivalents at beginning of the year	18,285	22,686	22,686	26,289
Net cash (used in) from operating activities	(96)	(6,972)	(5,948)	7,472
Net cash from (used in) investing activities	10,703	1,810	1,810	(1,853)
Net cash (used in) from financing activities	(7,019)	8,575	3,290	11,483
Net increase (decrease) in cash and cash equivalents	3,588	3,413	(848)	17,102
Effect of foreign exchange rate changes	813	190	(216)	406
	<u>813</u>	<u>190</u>	<u>(216)</u>	<u>406</u>
Cash and cash equivalents at end of the year	<u>22,686</u>	<u>26,289</u>	<u>21,622</u>	<u>43,797</u>

FINANCIAL INFORMATION

Net cash (used in) from operating activities

We derive our cash flow from operating activities principally from the receipt of payments for the sale of products. Our cash used in operating activities is primarily used to pay for costs and expenses relating to operating activities, and to fund our working capital.

For the year ended 31 December 2011, our cash used in operating activities was approximately HK\$96,000, while our operating cash flows before changes in working capital were approximately HK\$16,196,000. The cash outflow of approximately HK\$16,292,000 mainly reflected (i) an increase in trade and other receivables of approximately HK\$18,937,000 since we needed to give more deposits and prepayments to suppliers to secure their provision of products with market potential; (ii) a decrease in trade and other payables of approximately HK\$3,112,000 since that some Type 2 Distributor Customers terminated business relationships with us due to the expiration of the tender period of certain products, and we reduced the number of Type 3 Distributor Customers due to our intended business concentration; and (iii) income tax expenses of approximately HK\$4,225,000. These cash outflows were partially offset by (i) a decrease in inventories of approximately HK\$6,299,000, which was primarily due to our tighter control on inventory level and accelerated inventory turnover; and (ii) an increase in bill payables of approximately HK\$3,683,000 due to utilisation of banking facilities.

For the year ended 31 December 2012, our cash used in operating activities was approximately HK\$6,972,000, while our operating cash flows before changes in working capital were approximately HK\$22,490,000. The cash outflow of approximately HK\$29,462,000 mainly reflected (i) an increase in trade and other receivables of approximately HK\$14,573,000 since we needed to give more deposits and prepayments to certain suppliers to secure their provision of products with market potential; (ii) a decrease in trade and other payables of approximately HK\$2,847,000 since some Type 2 Distributor Customers terminated business relationships with us due to the expiration of the tender period of certain products, and we reduced the number of Type 3 Distributor Customers due to our intended business concentration; (iii) a decrease in bills payable of approximately HK\$3,723,000 since we had repaid the banking facilities; and (iv) income tax expenses of approximately HK\$6,886,000.

For the six months ended 30 June 2013, our cash from operating activities was approximately HK\$7,472,000, while our operating cash flows before changes in working capital were approximately HK\$9,009,000. The cash outflow of approximately HK\$1,537,000 mainly reflected (i) an increase in trade and other receivables of approximately HK\$2,535,000; (ii) income tax expenses of approximately HK\$3,573,000; and (iii) the increase in trade and other payables of approximately HK\$4,327,000 as a result of the increase in VAT payables and accruals.

Negative operating cashflow for each of the year ended 31 December 2011 and 2012

Our Group's negative operating cashflow for the year ended 31 December 2011 was primarily attributable to (i) the deposit of RMB1.5 million (equivalent to approximately HK\$1,849,000) paid to Xizang Yimingxiya Pharmaceutical Technology Company Limited* (西藏易明西雅生物醫藥科技有限公司) to acquire the exclusive distribution right of Lamivudine Tablets (拉米夫定片) in Zhejiang province, Jiangsu province and Shanghai, where the agreement was terminated on 21 November 2012 and the deposit was fully returned to our Group in December 2012 and March 2013, respectively; and (ii) a deposit of RMB1.0

FINANCIAL INFORMATION

million (equivalent to approximately HK\$1,232,000) paid to Lodays Pharmaceutical (Hubei) Company Limited* (朗天藥業(湖北)有限公司) to acquire the exclusive distribution right of Milrinone Lactate Injection (乳酸米力農注射液) in Zhejiang province in January 2012; and (iii) the increase in prepayments made to Kaihongxin and Baoding Huida of approximately HK\$4.3 million and HK\$7.7 million, respectively, which were netted off against the purchase from Kaihongxin and Baoding Huida in 2012.

Our Group's net cash outflow from operating activities for the year ended 31 December 2012 was primarily attributable to (i) the deposits paid to Kaihongxin of approximately RMB7 million (equivalent to approximately HK\$8,701,000) and Zhongcheng Huida of approximately RMB8 million (equivalent to approximately HK\$9,944,000) to secure the continual supply of our key products; our sales generated by Zhongcheng Huida's products were approximately HK\$51.9 million and HK\$61.4 million for the year ended 31 December 2011 and 2012 respectively, representing approximately 32.5% and 35.1% of our total revenue for the corresponding years, including the sales from our major products, namely (a) Cefodizime Sodium for Injection (注射用頭孢地嗪鈉); (b) Thoymosin α 1 for Injection (注射用胸腺法新); (c) Ispeamicin Sulfate for Injection (硫酸異帕米星注射液); (d) Alanyl Glutamine for Injection (注射用丙氨酸谷氨酰胺); and (e) Ceftizoxime Sodium for Injection (注射用頭孢噻肟鈉), which in aggregate were approximately HK\$43.6 million, HK\$57.3 million and HK\$28.7 million for the years ended 31 December 2011 and 2012 and the six months ended 30 June 2013, respectively. Our sales generated by Kaihongxin's products were approximately HK\$29.4 million and HK\$55.1 million for each of the two years ended 31 December 2011 and 2012, respectively, representing approximately 18.4% and 31.5% of our total revenue for the corresponding years, including the sales of Levocarnitine Injection (左卡尼汀注射液), which was approximately HK\$20.1 million, HK\$52.2 million and HK\$28.3 million for each of the two years ended 31 December 2011 and 2012 and the six months ended 30 June 2013, respectively; (ii) the deposits paid to Guizhou Jingfeng of approximately RMB2 million (equivalent to approximately HK\$2,486,000) for the distribution right of the new product with market potential for business expansion which is subject to the upcoming provincial collective tendering process; (iii) the increase in prepayments made to Kaihongxin of approximately RMB9,905,000 (equivalent to approximately HK\$12,350,000) while the prepayment made to Kaihongxin as at 31 December 2012 was fully netted off against the purchase from Kaihongxin for the three months ended 31 March 2013 and the prepayment paid for the return of Cefotaxime Sodium and Sulbactam Sodium for Injection 2.25g (注射用頭孢噻肟鈉舒巴坦鈉2.25g) of approximately HK\$8,182,000 as at 31 December 2012, Kaihongxin has fully resumed the supply of the product and the first batch of the product has arrived at our warehouse on 24 May 2013; and (iv) the Listing expenses of approximately HK\$8,567,000 for the year ended 31 December 2012, which is not expected to recur upon Listing.

In view of our current business operation, we are required to make substantial deposits to a majority of our suppliers, including pharmaceutical companies and pharmaceutical manufacturers to show our commitment in order to negotiate better terms for purchase and enter into a long term of contract with our suppliers and also prepayments to secure the stable supply of our products. The one-off deposit payment will be made to secure the distribution rights of the existing products and acquire the distribution rights of the new products with the market potential for business expansion, for improvement in the profitability of our Group in the long run. Our Directors are of the view that the deposit payments are one-off payment and refundable upon termination of the distribution agreements and the prepayment will be netted off against the purchase in the near future. However, there is timing difference between the payment of the deposits and these respective generated revenues. During the Track Record

FINANCIAL INFORMATION

Period, our Group paid the deposit of approximately RMB8 million, RMB7 million and RMB8 million to Type 1 Supplier A, Kaihongxin and Zhongcheng Huida, respectively, for the acquisition of distribution right and those deposits were recorded at the time of payment in 2011 and 2012, respectively, with immediate effect on the changes in the working capital of our combined cashflow statements. The respective revenues generated from those products for which we obtained the distribution rights were sufficient to cover the deposit payment within 1 to 2 financial year(s) following the payment of the respective deposits.

To use the working capital efficiently, our Group has negotiated with our existing suppliers and new suppliers to use the corporate guarantee provided by Hong Rui Bio-medical or any other subsidiary of the Company upon Listing instead of deposit payment for the acquisition of the distribution right. Each of Zhongcheng Huida, Kaihongxin and Jiangsu Baichang has agreed and confirmed with our Group in July 2013, confirming to return the deposit of RMB8 million, RMB7 million and RMB1 million held by Zhongcheng Huida, Kaihongxin and Jiangsu Baichang respectively upon Listing. Our Company will procure Hong Rui Bio-medical or any other subsidiary of the Company upon Listing as the guarantor for Zhongcheng Huida, Kaihongxin and Jiangsu Baichang, and Hong Rui Bio-medical or any other subsidiary of the Company upon Listing has to maintain a minimum cash balance for Zhongcheng Huida and Kaihongxin respectively during the guarantee period. The following table illustrates the arrangements for such corporate guarantee:

Name of the supplier	Amount of deposit paid to the supplier	The future arrangement	The minimum cash balance to be maintained by Hong Rui Bio-medical during the guarantee period
Zhongcheng Huida	RMB8 million	The supplier will fully return the deposit to our Group upon Listing, and will be provided with corporate guarantee for the distribution rights	RMB3 million
Kaihongxin	RMB7 million	The supplier will fully return the deposit to our Group upon Listing, and will be provided with corporate guarantee for the distribution rights	RMB2 million
Jiangsu Baichang	RMB1 million	The supplier will fully return the deposit to our Group upon Listing, and will be provided with corporate guarantee for the distribution rights	Nil

FINANCIAL INFORMATION

Our Company will disclose in its interim and annual reports after Listing regarding the progress of the foregoing corporate guarantee arrangements and subsequent return of deposit as and when appropriate.

Further, our Group has adopted the following measures to avoid imposing pressure on our working capital:

1. our Group has adopted certain criteria in assessment of potential suppliers and identification of new distribution rights of products by considering the market research and the feasibility report of the new products while negotiating the terms of deposit and prepayment for the acquisition of the distribution right of the new products and the renewal of the distribution right of the existing products;
2. our Group compiles a cash flow forecast monthly in order to supervise our cashflow position. The cash flow forecast assists our management to monitor our operation, in particular, the payment of deposit and prepayment for the acquisition of the distribution right of the new products and the inventory procurement. Our Group takes into consideration our cash position and availability of external financing at the time prior to the payment of deposits for a new distribution right of products;
3. our Group reviews the financial position of our major suppliers to which we have paid a large amount of deposits and/or prepayment annually. We will also liaise with the management of our major suppliers to understand their financial and operational capabilities and performances. Our Directors confirm that as at the Latest Practicable Date, none of our major suppliers has so far encountered any financial difficulty that may affect the repayment of our deposits and/or prepayments;
4. our Group has compiled a quarterly sales forecast to assist the management to determine the procurement of the inventory without accumulation, and the amount of prepayment should be made to our suppliers to ensure the stable supply of the products without making too much prepayments;
5. our Group will communicate with our suppliers and our Distributor Customers to monitor the trade and other receivables collection and payments to maintain a better cashflow position; and
6. our Group will identify and look for alternative funding sources to sustain or expand our business operation, when necessary. We are able to obtain bank borrowings and other loan facilities in view of our credit history during each of the two years ended 31 December 2011 and 2012, the six months ended 30 June 2013 and up to the Latest Practicable Date, respectively. We did not encounter any difficulty in raising funds during the Track Record Period and up to the Latest Practicable Date. We drewdown a loan of RMB8,500,000 from a pledged banking facilities from Agricultural Bank of China Limited – Hangzhou Jiefang Road branch* (中國農業銀行股份有限公司杭州解放路支行) on 10 January 2013 for the payment of the acquisition of the distribution right of new product. On 9 May 2013, Our Group was granted a loan facility of HK\$12,000,000 by a money lending company in Hong Kong, which is a licensed money lender in Hong Kong and save for such money lender's ultimate beneficial owner being interested approximately 5.13% of the shareholding in one of the Underwriters, an Independent Third Party. The interest rate of such loan was 6.0% per annum. On 17 June 2013, our Group was granted a banking facility from a licensed bank in Hong Kong of an overdraft of HK\$5,000,000 and a revolving loan of HK\$15,000,000.

FINANCIAL INFORMATION

The Sole Sponsor is of the view that our Group has the sufficient working capital for our present requirement for the next 12 months with reference to the recent operation, the financial position, the current cash position of our Group and after considering:

- a) **reason for the negative operating cash flow:** the negative operating cash flow for each of the two years ended 31 December 2011 and 2012 was primarily due to (i) the one-off payment of deposit to secure the distribution right generated the timing difference on the cashflow which affected the operating cashflow position immediately after the payment of deposits with profit generated within 1 to 2 financial year(s); (ii) the prepayment to secure the supply of the products; and (iii) the payment of Listing expenses;
- b) **internal control measures taken:** the internal control measures taken to safeguard (i) the deposit and prepayment of our Group and (ii) the working capital of our Group as mentioned above; and
- c) **its unutilised financing facilities:** the unutilised loan facilities from a money lender in Hong Kong and the unutilised banking facilities from a licensed bank in Hong Kong as at the Latest Practicable Date.

Net cash from (used in) investing activities

Our cash used in investing activities primarily consists of payments for the purchase of property, plant and equipment, placement of pledged bank deposits, and investment in and advance to a joint venture, Haikou Xin Lang. Our cash from investing activities primarily consists of withdrawals in pledged bank deposits and proceed from disposal of assets classified as held for sale and property, plant and equipment.

For the year ended 31 December 2011, our net cash from investing activities was approximately HK\$10,703,000. Our cash from investing activities was primarily due to proceed of disposal of assets classified as held for sale in amount of approximately HK\$13,564,000 in relation to the disposal of Shenyang Meiluo under a share transfer agreement dated 19 January 2011 entered into between Mr. He (being a nominee of Zhejiang Xin Rui Pharmaceutical) as transferor and an Independent Third Party as transferee. The cash inflow was partially offset by placements of pledge bank deposits in amount of approximately HK\$1,849,000.

For the year ended 31 December 2012, our net cash from investing activities was approximately HK\$1,810,000. Our cash from investing activities was primarily due to withdrawals of pledge bank deposits in a total amount of approximately HK\$1,849,000. The cash inflow was partially offset by purchase of property, plant and equipment of approximately HK\$174,000.

For the six months ended 30 June 2013, our net cash used in investing activities was approximately HK\$1,853,000. Our cash from investing activities was primarily due to the purchase of motor vehicle of approximately HK\$2,525,000.

Net cash (used in) from financing activities

Our cash flow from financing activities consists of an increase in advance from related parties and new borrowing raised. Our cash flows used in financing activities consists of repayment to related parties and interest paid and expenses paid in connection with the Listing.

FINANCIAL INFORMATION

For the year ended 31 December 2011, our net cash used in financing activities was approximately HK\$7,019,000, which was due to (i) advance from related parties, subsidiaries of Town Health International and Yang Qi (楊奇) of approximately HK\$1,049,000; (ii) repayment to related parties, subsidiaries of Town Health International and Yang Qi of approximately HK\$7,881,000; and (iii) interest paid in amount of approximately HK\$187,000.

For the year ended 31 December 2012, our net cash from financing activities was approximately HK\$8,575,000, which was due to (i) a new borrowing of approximately HK\$12,000,000 to settle Listing expenses of our Group; (ii) advance from related parties, subsidiaries of Town Health International and Yang Qi (楊奇), Ms. Yang's brother of approximately HK\$3,872,000; (iii) repayment to related parties, subsidiaries of Town Health International and Yang Qi (楊奇), Ms. Yang's brother of approximately HK\$4,876,000; (iv) interest paid in the amount of approximately HK\$38,000; and (v) expenses paid in connection with the Listing of approximately HK\$2,383,000.

For the six months ended 30 June 2013, our net cash from financing activities was approximately HK\$11,483,000, which was mainly due to (i) a new borrowing of approximately HK\$16,736,000; (ii) net repayment to related parties of approximately HK\$554,000; (iii) interest paid in the amount of approximately HK\$841,000; and (iv) expenses paid in connection with the Listing of approximately HK\$3,858,000.

Net Current Assets

The following table sets forth current assets, current liabilities and net current assets from our combined statements of financial position as of the dates indicated:

	As of 31 December		As of	As of
	2011	2012	30 June	31 August
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>
				(Unaudited)
Current Assets				
Inventories	14,916	16,151	16,199	17,709
Trade and other receivables	80,779	108,462	97,678	94,109
Bill receivables	–	292	–	–
Prepaid lease payments	189	191	194	195
Amounts due from related parties	80	80	80	–
Pledged bank deposits	1,849	–	–	5,000
Bank balances and cash	22,686	26,289	43,797	36,422
Total current assets	120,499	151,465	157,948	153,435

FINANCIAL INFORMATION

	As of 31 December		As of	As of
	2011	2012	30 June	31 August
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>2013</i>	<i>2013</i>
			<i>HK\$'000</i>	<i>HK\$'000</i>
				(Unaudited)
Current Liabilities				
Trade and other payables	17,680	14,929	19,256	11,552
Bills payables	3,697	–	–	–
Amounts due to related parties	1,547	554	–	–
Bank and other borrowings – due within one year	–	12,000	28,736	28,788
Tax payable	1,110	1,868	2,213	1,516
	<u>24,034</u>	<u>29,351</u>	<u>50,205</u>	<u>41,856</u>
Total current liabilities				
	<u>24,034</u>	<u>29,351</u>	<u>50,205</u>	<u>41,856</u>
Net current assets	<u>96,465</u>	<u>122,114</u>	<u>107,743</u>	<u>111,579</u>

We had net current assets of approximately HK\$96,465,000, HK\$122,114,000, HK\$107,743,000 and HK\$111,579,000 as of 31 December 2011, 31 December 2012, 30 June 2013 and 31 August 2013, respectively.

Working Capital

Our Directors are of the opinion that after taking into account the cash flow generated from operating activities, the existing financial resources available to our Group including internally generated funds, the available banking and unsecured loan facilities and the estimated net proceeds of the Placing, our Group has sufficient working capital for our present requirements for at least the next 12 months from the date of this prospectus.

FINANCIAL INFORMATION

Inventories

Our inventories primarily consist of finished goods that we purchase from our suppliers for resale through our distribution network. We actively monitor and adjust our inventory based on the levels of products being despatched and our operations team monitors the stock on a regular basis. Additionally, we use our inventory management system to manage our inventories.

We seek to maintain a relatively low level of inventories due to the nature of the pharmaceutical products. We typically maintain 30-45 days' worth of inventories at any given time.

	As of 31 December		As of
	2011	2012	30 June
	<i>HK\$'000</i>	<i>HK\$'000</i>	2013
			<i>HK\$'000</i>
Finished goods	14,916	16,151	16,199

As of 31 December 2012, our inventories increased by approximately 8.3%, to approximately HK\$16,151,000 from approximately HK\$14,916,000 as of 31 December 2011. This increase was in line with the increase in revenue. As of 30 June 2013, our inventory level remained stable and recorded at HK\$16,199,000 as at 30 June 2013.

The following table sets forth an aging analysis of our inventories, based on the date of receipt of inventory, as of the dates indicated:

	As of 31 December				As of 30 June	
	2011		2012		2013	
	Amount		Amount		Amount	
	<i>HK\$'000</i>	<i>(%)</i>	<i>HK\$'000</i>	<i>(%)</i>	<i>HK\$'000</i>	<i>(%)</i>
Within 90 days	14,224	95.4	16,001	99.1	11,092	68.5
90 – 365 days	689	4.6	150	0.9	5,107	31.5
Over 365 days	3	0.0	–	–	–	–
Total	14,916	100.0	16,151	100.0	16,199	100.0

FINANCIAL INFORMATION

The following table sets forth the components of our inventory as of 30 June 2013:

Product	1-90 days HK\$'000	Over 91 days HK\$'000	Total amount HK\$'000	Expiry date (%)
Levocarnitine Injection (左卡尼汀注射液)	6,090	–	6,090	37.6
Sulbenicillin Sodium for Injection (注射用磺苄西林鈉)	–	4,727	4,727	29.2
Cefodizime Sodium for Injection 0.5g (注射用頭孢地噻啉0.5g)	1,172	256	1,428	8.8
Cefixime Dispersible Tablet (頭孢克肟分散片)	1,121	39	1,160	7.2
Others	2,709	85	2,794	17.2
Total	11,092	5,107	16,199	100.0

Pursuant to the tri-partite agreement entered by Shenyang Meiluo, Type 1 Supplier A and our Group in July 2012, Type 1 Supplier A has undertaken to our Group that the exclusive national distribution rights of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) are retained by our Group. The production and supply of the product have been resumed in August 2012 and October 2012, respectively by Type 1 Supplier A. Hence, we made a large amount of purchase of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) for the preparation of national distribution.

The following table sets forth the turnover days of our inventories for the periods indicated:

	Year ended 31 December		Six months ended
	2011	2012	30 June 2013
Turnover days of inventory	47	42	45

Note: Turnover days of inventory is derived by dividing the average of the opening and closing balances of inventory for the relevant period by cost of sales and multiplying this figure by 365 days for a year or 183 days for six months. As of 31 December 2010, we had inventories of approximately HK\$20,574,000.

FINANCIAL INFORMATION

Our inventory turnover days were at a low level and generally stable, and decreased from 47 days for the year ended 31 December 2011 to 42 days for the year ended 31 December 2012, and to 45 days for the six months ended 30 June 2013.

As of the Latest Practicable Date, we sold out inventory of approximately HK\$12,461,000, representing approximately 76.9% of outstanding balance amount of our inventory as of 30 June 2013.

Due to the development of national distribution network and the pending status of various provincial collective tendering processes, the subsequent sales of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) were limited for the six months ended 30 June 2013. We sold Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) of approximately HK\$4,012,000, representing approximately 52.9% of our inventory of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) of approximately HK\$7,586,000 as at 31 December 2012. Our Group has obtained the exclusive national distribution rights of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) from Type 1 Supplier A, and our Directors consider that (i) the average monthly subsequent sales of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) for the six months ended 30 June 2013 was approximately HK\$669,000, which have improved as compared to the average monthly sales of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) since October 2012 of approximately HK\$214,000; (ii) the expiry date of the current inventories of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) is October 2014 and according to the PICO Report, the pharmaceutical distributors normally purchase pharmaceutical products with a valid period of not less than half year; and (iii) as encouraged by the government policy, the pharmaceutical products manufactured by the pharmaceutical manufacturers which have complied and satisfied the revised GMP standards will have a relatively better chance to win the tender during various provincial collective tendering process. Hence our Directors are of the view that the net realisable value of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) is higher than its cost and therefore our Group has not been required to make impairment provision according to the impairment provisioning policy for inventory. In addition, our Group has not acquired any inventory of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) since 31 December 2012 and up to the Latest Practicable Date and has no plan to acquire further inventories of such product until the current inventories have been substantially sold.

We ceased sales of Ozagrel Sodium for Injection (注射用奧紮格雷鈉) of 20mg specification in October 2012, and both 40mg and 80mg specifications of such products in June 2013. As at the Latest Practicable Date, we sold out all previously purchased Ozagrel Sodium for Injection (注射用奧紮格雷鈉) at profit, and no longer have any inventory.

FINANCIAL INFORMATION

Trade, bills and other receivables

Our trade, bills and other receivables mainly represent amounts owed to us by our customers who purchased products from us with credit terms. The following table sets forth our trade and other receivables as of the dates indicated:

	As of 31 December		As of
	2011	2012	30 June
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>2013</i>
			<i>HK\$'000</i>
Trade receivables	48,149	41,409	45,506
Bills receivables	–	292	–
	<hr/>	<hr/>	<hr/>
Sub-total	48,149	41,701	45,506
	<hr/>	<hr/>	<hr/>
Other receivables			
Other prepayments	478	426	825
Deferred listing expenses	–	2,383	6,241
Prepayments to suppliers	26,082	28,206	27,792
Deposits paid to suppliers	5,957	35,778	17,052
Others	113	260	262
	<hr/>	<hr/>	<hr/>
Sub-total	32,630	67,053	52,172
	<hr/>	<hr/>	<hr/>
Total	<u>80,779</u>	<u>108,754</u>	<u>97,678</u>

(i) *Trade and bills receivables*

As of 31 December 2012, our trade and bills receivables decreased by approximately 13.4%, to approximately HK\$41,701,000 from approximately HK\$48,149,000 as of 31 December 2011. This decrease was primarily due to our tighter account receivables collection policy. We require some Type 2 Distributor Customers and Type 3 Distributor Customers to pay before the delivery of the goods. As of 30 June 2013, the trade and other receivables recorded as approximately HK\$45,506,000.

FINANCIAL INFORMATION

We allow a credit period of 30 to 90 days to our Distributor Customers in general during the Track Record Period, except Hainan Xinmei Medicine Company Limited* (海南新美醫藥有限公司) (“**Hainan Xinmei**”) with a previous credit period of 180 days in 2011, and the credit period shortened to 90 days on 1 August 2012. The following table sets forth an aging analysis of trade and bills receivables presented based on the invoice date at the end of the reporting period as of the dates indicated:

	As of 31 December				As of 30 June	
	2011		2012		2013	
	Amount HK\$'000	(%)	Amount HK\$'000	(%)	Amount HK\$'000	(%)
0 – 30 days	18,965	39.4	20,790	49.9	21,764	47.8
31 – 60 days	17,521	36.4	19,642	47.1	20,700	45.5
61 – 90 days	2,621	5.4	396	0.9	2,156	4.7
91 – 180 days	4,253	8.8	873	2.1	886	2.0
Over 180 days	4,789	10.0	–	–	–	–
Total	48,149	100.0	41,701	100.0	45,506	100.0

As of 31 December 2011, approximately 39.4% and 36.4% of our trade and bills receivables would be collected within 30 days and 31–60 days, respectively, while approximately 49.9% and 47.1% of trade and bills receivables would be collected within 30 days and 31–60 days, respectively as of 31 December 2012 and approximately 47.8% and 45.5% of trade and bills receivables would be collected within 30 days and 31–60 days, respectively, as of 30 June 2013.

We generally grant longer credit terms to our Type 1 Distributor Customers, as compared with those to Type 2 Distributor Customers, because our major Type 1 Distributor Customers have a larger scale of operation with better reputation, and the payment collection periods of Type 1 Distributor Customers from hospitals were generally longer. For Type 2 Distributor Customers, we usually require them to pay in advance.

As of the Latest Practicable Date, we have collected trade and bills receivables of approximately HK\$43,348,000, representing approximately 95.3% of outstanding balance amount of our trade and bills receivables as of 30 June 2013.

The following table sets forth the turnover days of our trade receivables for the periods indicated:

	Six months ended 30		
	Year ended 31 December 2011	2012	June 2013
Turnover days of trade and bills receivables	<u>107</u>	<u>94</u>	<u>95</u>

Note: Turnover days of trade and bills receivables is derived by dividing the average of the opening and closing balances of trade and bills receivables for the relevant period by revenue and multiplying this figure by 365 days for a year or 183 days for six months. As of 31 December 2010, we had trade and bills receivables of approximately HK\$45,109,000.

FINANCIAL INFORMATION

Our trade and bills receivables turnover days decreased from 107 days for the year ended 31 December 2011 to 94 days and 95 days for the year ended 31 December 2012 and for the six months ended 30 June 2013. The trade and bills receivables turnover days are general in line with the credit period we have granted to our customers. We granted a credit period of 180 days for some business transactions with Hainan Xinmei, which is an Independent Third Party owned by the spouse of our finance manager, Ms. Zhang Qiao, and mainly distributed our products to medium and small size medical institutions with longer payment collection periods during the Track Record Period. We did not have long-term business relationship with any other Distributor Customers engaged in distributing pharmaceutical products to medium and small size medical institutions. On 1 August, 2012, a supplemental agreement was entered into between our Group and Hainan Xinmei to shorten the credit period from 180 days to 90 days. For the year ended 31 December 2011, the unit prices of 5 out of 26 product specifications we sold to Hainan Xinmei were 10% lower than the unit prices of the same products we sold to other Type 2 Distributor Customers, whereas the unit prices of the other 22 products were not 10% lower than or even higher than the unit prices of the same products we sold to other Type 2 Distributor Customers, where the revenue from Hainan Xinmei amounted to approximately HK\$12,299,000, representing approximately 7.7% of our total revenue. For the year ended 31 December 2012, the unit prices of 8 out of 24 product specifications we sold to Hainan Xinmei were 10% lower than the unit prices of the same products we sold to other Type 2 Distributor Customers, whereas the unit prices of the other 16 products were not 10% lower than or even higher than the unit prices of the same products we sold to other Type 2 Distributor Customers, where the revenue from Hainan Xinmei amounted to approximately HK\$944,000, representing approximately 0.5% of our total revenue. Our Directors consider that Hainan Xinmei mainly distributes our products to medium and small size medical institutions, and thus it is reasonable to offer a lower price as compared to other Type 2 Distributor Customers to Hainan Xinmei for certain products we sold to them. Hainan Xinmei was the only Distributor Customer with the credit period of 180 days during the Track Record Period. We have established business relationship with Hainan Xinmei since 2010. The outstanding balance of trade receivable from Hainan Xinmei as at 30 June 2013 was approximately HK\$97,000.

Before accepting any new customers, our Group assesses the potential customer's credit quality and prescribe the relevant credit limits for the customer. The credit limits attributed to customers are reviewed periodically. A majority of the trade receivables that are neither past due nor impaired have no default payment history.

Included in our Group's trade receivable balance are debtors with aggregate carrying amount of approximately HK\$4,789,000, HK\$873,000 and HK\$886,000 which were considered past due as at 31 December 2011, 31 December 2012 and 30 June 2013, respectively. For the provisioning policy of trade and other receivable, our Group makes allowances for doubtful debts based on an assessment of the recoverability of trade receivables. Allowances are applied to trade receivables where events or changes in circumstances indicate that the balances may not be collectible. During the Track Record Period, our Group has not provided for impairment loss because our management is of the opinion the fundamental credit quality of these customers has not been deteriorated. Our Group does not hold any collateral over these balances. During the Track Record Period, the average settlement periods for our major Distributor Customers, including state-owned enterprises, were 90 to 120 days. Trade and bill receivables of all Distributor Customers were settled within 60 days after due

FINANCIAL INFORMATION

date during the Track Record Period. Therefore, save for the incident regarding cessation in supply of the Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) from Shenyang Meiluo as disclosed in the section headed, “Product shortage from our suppliers during Track Record Period” under the sub-section headed “Phase 2 – Procurement of Products from our suppliers” under the section headed “Business” of this prospectus, we did not experience any material default and/or delay in settlement by our Distributor Customers.

(ii) *Other receivables*

Other receivables comprise other prepayments, prepaid Listing expenses, prepayments to suppliers, deposits to suppliers, and other receivables. Our prepayments, prepayments to suppliers, deposits to suppliers, and other receivables were approximately HK\$32,630,000, HK\$67,053,000 and HK\$52,172,000 as of 31 December 2011, 31 December 2012 and 30 June 2013, respectively. The increase for the year ended 31 December 2012 was primarily due to (i) the prepaid Listing expenses of approximately HK\$2,383,000 for the year ending 31 December 2013; (ii) an increase in prepayments to suppliers of approximately HK\$2,124,000; and (iii) a significant increase in deposits paid to suppliers of approximately HK\$29,821,000. For the six months ended 30 June 2013, the decrease was primarily due to the decrease in the deposits paid to suppliers as a result of the reclassification of the deposit to Kaihongxin and Zhongcheng Huida as non-current assets, which was partially offset by the increase in the deferred Listing expenses.

We will be required to pay deposits to our suppliers in order to guarantee not to breach the contracts, prevent cannibalisation and ensure commitment to the sales targets. We will also be required to pay for the purchases before the delivery as prepayment to secure a stable supply of the products. According to the PICO Report, the pharmaceutical distributors may make deposit and/or prepayment to pharmaceutical manufacturers or the pharmaceutical companies with exclusive distribution rights, especially for the products with market potential. The prepayment will be netted off against the amount of our subsequent purchase. The amount of prepayment has been determined by the recent sales amount, our inventory level and current market conditions. In the event that the distribution agreement entered into between the suppliers and us is due or terminated upon mutual consent and without any violation of the terms as set out in the distribution agreement, the deposits and the unutilised prepayments will be fully returned to our Group within the period of time as set out in the distribution agreement. Please refer to the section headed “Business – Our business model – Phase 1 – Acquisition of distribution rights of pharmaceutical products from our suppliers – Step 3 – Assistance and co-ordination in provincial collective tendering process of the new products for our suppliers – Distribution Agreements between our Group and our suppliers – Deposits and Prepayments” for further details and the safeguard measures for our prepayments and deposits. During the Track Record Period and as at the Latest Practicable Date, our Group did not experience any confiscation of deposits or unutilised prepayments by our suppliers as a result of violation of the terms as set out in the respective distribution agreements.

FINANCIAL INFORMATION

Deposits and prepayments

The following table sets forth a breakdown of deposits to our major suppliers during the Track Record Period.

	As at 31 December		As at 30 June
	2011	2012	2013
	Amount	Amount	Amount
	(RMB'000)	(RMB'000)	(RMB'000)
Deposits			
Non-current			
Type 1 Supplier A (Note 1)	8,000	–	–
Kaihongxin (Note 2)	–	–	6,061
Zhongcheng Huida (Note 3)	–	–	6,927
	<u>8,000</u>	<u>–</u>	<u>13,000</u>
Current			
Type 1 Supplier A (Note 1)	–	8,000	8,000
Kaihongxin (Note 2)	–	7,000	–
Zhongcheng Huida (Note 3)	–	8,000	–
Guizhou Jingfeng (Note 4)	–	2,000	2,000
Xizang Yimingxiya	1,500	450	–
Lodays Pharmaceutical (Hubei) Company Limited* (朗天藥業(湖北)有限公司)	1,000	1,000	1,000
Beijing Jiacheng Pharmaceutical Company Limited* (北京佳誠醫藥有限公司)	806	806	–
Type 1 Supplier B	260	250	250
Hainan Noken Pharmaceutical Industry Ltd.* (海南諾爾康藥業有限公司) (Note 5)	–	900	1,000
Beijing Haoyafangda Medicine Co., Ltd.* (北京浩雅方大醫藥有限公司) (Note 6)	–	–	1,000
Others	1,268	378	250
	<u>4,834</u>	<u>28,784</u>	<u>13,500</u>
Total current deposits	4,834	28,784	13,500
	(equivalent to approximately HK\$5,957,000)	(equivalent to approximately HK\$35,778,000)	(equivalent to approximately HK\$17,052,000)
Total	<u>12,834</u> (Note 7)	<u>28,784</u>	<u>26,488</u> (Note 7)
	(equivalent to approximately HK\$14,573,000)	(equivalent to approximately HK\$35,778,000)	(equivalent to approximately HK\$33,456,000)

FINANCIAL INFORMATION

- Note 1:* The deposit was previously paid to Shenyang Meiluo and transferred to Type 1 Supplier A for supply of Sulbencillin Sodium for Injection (注射用磺苄西林鈉) pursuant to the tri-partite agreement entered into among Shenyang Meiluo, Type 1 Supplier A and our Group in July 2012.
- Note 2:* The deposit paid to Kaihongxin was to secure their continuous supply of 8 products, including Levocarnitine Injection (左卡尼汀注射液) pursuant to the distribution agreement dated 22 November 2012. The deposits paid to Kaihongxin during the period of the six months ended 30 June 2013 was classified as non-current asset as a result of the renewal of contract which will expire on 31 December 2015.
- Note 3:* The deposit paid to Zhongcheng Huida was to secure their continuous supply of 9 products, including our major products such as Cefodizime Sodium for Injection (注射用頭孢地噻鈉), Thoymosin α 1 for Injection (注射用胸腺法新), Iseamicin Sulfate for Injection (硫酸異帕米星注射液) and Alanyl Glutamine for Injection (注射用丙氨酰谷氨酰胺) pursuant to the distribution agreement dated 20 November 2012. The deposit paid to Zhongcheng Huida during the period of the six months ended 30 June 2013 was classified as non-current asset as a result of the renewal of contract which will expire on 31 December 2015.
- Note 4:* The deposit paid to Guizhou Jingfeng was to acquire the exclusive distribution right of Salviae Miltiorrhizae Liguspyrargine Hydrochloride and Glucose Injection (參芎葡萄糖注射液) in Zhejiang province pursuant to the distribution agreement dated 2 July 2012.
- Note 5:* The deposit paid to Hainan Noken Pharmaceutical Industry Ltd. of RMB11.0 million was to secure the potential national exclusive distribution right of Fasudil Hydrochloride Injection (鹽酸法舒地爾氯化鈉注射液) and one of the two products, namely, Multiple Electrolytic and Invert Sugar Injection (轉化糖注射液) and Ozagrel of Sodium for Injection (注射用奧紮格雷鈉) pursuant to the distribution agreement made in August 2012 and January 2013, respectively. On 28 June 2013, it had fully returned RMB10 million deposit since the separate pricing status of the target products could not be obtained from NDRC before 30 June 2013.
- Note 6:* The deposit paid to Beijing Haoyafangda Medicine Co., Ltd. was to acquire two exclusive distribution rights of products, namely Cervus and Cucumis Polypeptide for Injection (骨瓜提取物注射液) and Desmopressin Acetate Injection (醋酸去氨加壓素注射液) in Zhejiang province pursuant to the distribution agreements dated 21 January 2013 and 28 April 2013, respectively.
- Note 7:* The current portion of deposit of approximately RMB4,834,000 was equivalent to HK\$5,957,000 as at 31 December 2011. The current portion of deposit of approximately RMB13,500,000 was equivalent to HK\$17,052,000 as at 30 June 2013.

FINANCIAL INFORMATION

Our deposit shall be subject to the deduction in the event that (i) our Group does not meet the sales target; (ii) the market cannibalisation among the distributors exists; (iii) our Group fails to assist the suppliers in winning the provincial collective tendering process; and (iv) our Group fails to develop the hospital network within a certain period of time. In addition, the deposit will be returned to our Group if the production permit cannot be granted within a certain period of time.

For the year ended 31 December 2011, our Group paid a deposit of RMB1.5 million (equivalent to approximately HK\$1,849,000) to Xizang Yimingxiya Pharmaceutical Technology Company Limited* (西藏易明西雅生物醫藥科技有限公司) to enter into a legally binding contract before acquiring the exclusive distribution right of Lamivudine Tablets (拉米夫定片) in Zhejiang province, Jiangsu province and Shanghai. The agreement was terminated on 21 November 2012, and the deposit was fully returned to our Group in December 2012 and March 2013, respectively. On the other hand, our Group paid a deposit of RMB1.0 million (equivalent to approximately HK\$1,232,000) to Lodays Pharmaceutical (Hubei) Company Limited* (朗天藥業(湖北)有限公司) to acquire the exclusive distribution right of Milrinone Lactate Injection (乳酸米力農注射液) in Zhejiang province.

For the year ended 31 December 2012, the significant increase in deposits paid to suppliers was primarily due to (i) our payment of new deposits as requested by the suppliers to Kaihongxin, Zhongcheng Huida and Guizhou Jingfeng of approximately RMB7 million (equivalent to approximately HK\$8,701,000), RMB8 million (equivalent to approximately HK\$9,944,000) and RMB2 million (equivalent to approximately HK\$2,486,000), respectively, to secure their provision of products with market potentials; and (ii) the reclassification of the deposits paid to Type 1 Supplier A of approximately RMB8 million as current assets. Below is the analysis of the deposits paid to our major suppliers, Zhangcheng Huida and Kaihongxin in 2012:

(i) Deposits paid to Zhongcheng Huida

We commenced the business with Zhongcheng Huida since 2009 and have established 4 years of business relationship with Zhongcheng Huida. Baoding Huida originally did not require us to pay for any deposit of the distribution of its products since our Group required time to build up the provincial distribution network and had negotiated with them to waive the payment of deposit of RMB8 million (equivalent to HK\$9,944,000) till the year ended 31 December 2011. In view that (i) there was a change in the ultimate shareholder of Baoding Huida in January 2012; and (ii) Zhongcheng Huida was one of our two largest suppliers including the supply of our 5 major types of products (including 6 specifications) namely, Cefodizime Sodium for Injection (注射用頭孢地嗪鈉), Thoymosin α 1 for Injection (注射用胸腺法新), Ispemicin Sulfate for Injection (硫酸異帕米星注射液), Alanyl Glutamine for Injection (注射用丙氨醯穀氨醯胺) and Ceftizoxime Sodium for Injection (注射用頭孢唑肟鈉) during the Track Record Period, our sales generated by Zhongcheng Huida's products were approximately HK\$51.9 million, HK\$61.4 million and HK\$30.6 million for each of the two years ended 31 December 2011 and 2012 and the six months ended 30 June 2013, respectively, representing approximately 32.5%, 35.1% and 36.4% of our total revenue for the corresponding periods. The sales contributed from the aforesaid major products were approximately HK\$43.6 million, HK\$57.3 million and HK\$28.7 million, representing approximately 27.3%, 32.7% and 34.4% of our total revenue for each of the two years ended 31 December 2011 and 2012 and the six months ended 30 June

FINANCIAL INFORMATION

2013, respectively. We paid a deposit of RMB8 million to Zhongcheng Huida in January 2012, which is classified as non-current assets, immediately after the renewal of contracts on 7 January 2012 to secure their continuous supply of 10 products for the period from 1 January 2012 to 31 December 2012. The contract with Zhongcheng Huida was further renewed on 20 November 2012 for the continuous supply of 9 products including those 5 types of major products for the period from 1 January 2012 to 31 December 2015.

The deposit paid to Zhongcheng Huida in the amount of RMB\$8 million shall be subject to deduction (i) if the Group could not meet 80% of the prescribed sales target, that is, RMB40 million each year until the year ending 31 December 2015, and the amount of deposits is subject to deduction in proportion to the sales value of the products which the Group did not meet the sales target; and (ii) if the Group were to cannibalise the markets in other provinces, and (iii) the amount of deposits is subject to deduction in proportion to the sales value of the product in such market which the Group cannibalised.

During the Track Record Period and as at the Latest Practicable Date, our Group did not experience any confiscation of deposits by Zhongcheng Huida as a result of violation of the terms as set out in the respective distribution agreements.

(ii) Deposits paid to Kaihongxin

We commenced the business with Kaihongxin since 2008 and have established over 5 years of business relationship with Kaihongxin. Kaihongxin originally did not require us to pay for any deposit of the distribution of its products since we required time to build up the provincial distribution network and had negotiated with them to waive the payment of deposit of RMB7 million (equivalent to HK\$8,701,000) till the year ended 31 December 2011. In view that Kaihongxin was one of our two largest suppliers, and the supplier of one of our major products, namely, Levocarnitine Injection (左卡尼汀注射液) during the Track Record Period, our sales generated by Kaihongxin's products were approximately HK\$29.4 million, HK\$55.1 million and HK\$33.2 million for each of the two years ended 31 December 2011 and 2012 and the six months ended 30 June 2013, respectively, representing approximately 18.4%, 31.5% and 39.4% of our total revenue for the corresponding periods. The sales contributed from Levocarnitine Injection (左卡尼汀注射液) amounted to approximately HK\$20.1 million, HK\$52.2 million and HK\$28.3 million, representing approximately 12.6%, 29.8% and 33.8% of our total revenue for each of the two years ended 31 December 2011 and 2012 and the six months ended 30 June 2013, respectively. We paid a deposit of RMB7 million to Kaihongxin in May 2012, which is classified as non-current assets, for the renewal of contracts on 22 November 2012 to secure their continuous supply of 8 products for the period from 1 January 2013 to 31 December 2015.

FINANCIAL INFORMATION

The deposits paid to Kaihongxin amounted to RMB\$7 million, (i) shall be subject to deduction if the Group were to cannibalise the markets in the other provinces, and (ii) the amount of deposits is subject to deduction in proportion to the sales value of the product in such market.

During the Track Record Period and as at the Latest Practicable Date, our Group did not experience any confiscation of deposits by Kaihongxin as a result of violation of the terms as set out in the respective distribution agreements.

Our Directors are of the view that payment of the deposits in the amounts of RMB8 million and RMB7 million to Zhongcheng Huida and Kaihongxin, respectively, is justifiable since (i) the increasing popularity of the products from Zhongcheng Huida and Kaihongxin during the Track Record Period as reflected from their sales performances; and (ii) the deposits will be returned to our Group if our Group does not violate any of the terms as set out in the distribution agreements. Please refer to the section headed “Business – Our business model – Phase 2 – Procurement of products from our suppliers – Distribution Agreements on our major products with our major suppliers” of this prospectus for details of our distribution agreements with Zhongcheng Huida and Kaihongxin, respectively.

In addition, our Group paid a deposit of RMB2 million (equivalent to approximately HK\$2,486,000) to Guizhou Jingfeng as stated in the distribution agreement entered into between Guizhou Jingfeng and us on 2 July 2012 to acquire the exclusive distribution right of *Salviae Miltiorrhizae Liguspyragine Hydrochloride* and *Glucose Injection* (參芎葡萄糖注射液) in Zhejiang province for our business expansion.

For the six months ended 30 June 2013, we paid (i) a new deposit of RMB10 million (equivalent to approximately HK\$12,587,000) to Hainan Noken Pharmaceutical Industry Ltd.* (海南諾爾康藥業有限公司) as stated in the legally binding contract entered into between Hainan Noken Pharmaceutical Industry Ltd.* (海南諾爾康藥業有限公司) and us on January 2013 to secure the potential national exclusive distribution right of one of two products, namely, *Multiple Electrolytic and Invert Sugar Injection* (轉化糖注射液) and *Ozagrel of Sodium for Injection* (注射用奧紮格雷鈉), which was subsequently returned to us on 28 June 2013 as both *Multiple Electrolytic and Invert Sugar Injection* (轉化糖注射液) and *Ozagrel of Sodium for Injection* (注射用奧紮格雷鈉) failed to obtain the separate pricing status before 30 June 2013; and (ii) a deposit of RMB1 million (equivalent to approximately HK\$1,259,000) to Beijing Haoyafangda Pharmaceutical Company Limited* (北京浩雅方大醫藥有限公司) as stated in two distribution agreements entered into between Beijing Haoyafangda Pharmaceutical Company Limited* (北京浩雅方大醫藥有限公司) and us on 21 January 2013 and 28 April 2013, respectively, to acquire two exclusive distribution rights of products, namely *Cervus and Cucumis Polypeptide for Injection* (骨瓜提取物注射液) and *Desmopressin Acetate Injection* (醋酸去氧加壓素注射液) in Zhejiang province. We had ceased business relationship with Beijing Jiacheng Pharmaceutical Company Limited* (北京佳誠醫藥有限公司), and the deposit and prepayment paid to such supplier were returned to us in March 2013.

FINANCIAL INFORMATION

On 3 July 2013, Zhongcheng Huida and Kaihongxin confirmed to return the deposit of RMB8 million and RMB7 million, respectively, to us upon Listing. In July 2013, our Group entered into an exclusive provincial distribution agreement with Jiangsu Baichang in relation to a product, namely Kangfuxin Ye (康复新液). Jiangsu Baichang also confirmed to return the deposit of RMB1 million to us upon Listing. Our Company will procure Hong Rui Bio-medical or any other subsidiary of the Company as the guarantor for Zhongcheng Huida, Kaihongxin and Jiangsu Baichang, and Hong Rui Bio-medical or such other subsidiary of the Company is required to maintain the minimum cash balance of RMB3 million and RMB2 million for each of Zhongcheng Huida and Kaihongxin, respectively, during the guarantee period.

During the Track Record Period and as at the Latest Practicable Date, our Group did not experience any confiscation of deposits by our suppliers as a result of violation of the terms as set out in the respective distribution agreements.

The following table sets forth an aging analysis of our deposits as at 31 December 2011, 31 December 2012 and 30 June 2013, respectively:

	As at 31 December		2012		As at	
	2011		2012		30 June	
	Amount		Amount		Amount	
	<i>RMB'000</i>	<i>(%)</i>	<i>RMB'000</i>	<i>(%)</i>	<i>RMB'000</i>	<i>(%)</i>
Less than						
1 year	2,918	22.7	18,010	62.5	3,110	11.7
1 year to						
2 years	9,916	77.3	1,518	5.3	13,898	52.5
Over 2 years	–	–	9,256	32.2	9,480	35.8
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Total	<u>12,834</u>	<u>100.0</u>	<u>28,784</u>	<u>100.0</u>	<u>26,488</u>	<u>100.0</u>

Payment of the deposits for 1 year to 2 years as at 31 December 2011 and the deposits for over 2 years as at 31 December 2012 and 30 June 2013 was mainly attributable to the deposits paid to Type 1 Supplier A. The deposit to Type 1 Supplier A will be subject to deduction if we cannibalise the markets in the other provinces of our suppliers. Our Directors are of the view that the deposit to Type 1 Supplier A is recoverable with the consideration that (i) our Group tends to renew the contract with Type 1 Supplier A upon expiry of the existing contract on 1 July 2013 as the revised GMP status of Type 1 Supplier A would enhance its chance to win the upcoming provincial collective tendering process; (ii) the improved sales performance of Sulbencillin Sodium for Injection (注射用磺苄西林鈉) as disclosed in the paragraph headed “Inventories” of the section headed “Financial Information” in this prospectus; and (iii) the ability of Type 1 Supplier A to repay the deposit given that the deposit is immaterial to the net asset value of Type 1 Supplier A as at 31 December 2012. In addition, the deposit to Type 1 Supplier A will be fully returned to our Group upon the end of the distribution agreement. The revenue generated by Sulbencillin Sodium for Injection (注射用磺苄西林鈉), which was currently manufactured by Type 1 Supplier A, amounted to approximately HK\$10.4 million, HK\$0.6 million and HK\$4.0 million for each of the two years ended 31 December 2011 and 2012, and the six months ended 30 June 2013, respectively.

FINANCIAL INFORMATION

The following table sets forth a breakdown of prepayments to our major suppliers during the Track Record Period:

	As at 31 December		As at
	2011	2012	30 June
	Amount	Amount	Amount
	RMB'000	RMB'000	RMB'000
Prepayment			
Kaihongxin	3,512	13,417	15,308
Baoding Huida and/or Zhongcheng Huida	6,282	6,161	6,282
Shenyang Meiluo and/or Type 1 Supplier A	1,669	-	-
Beijing Jiacheng Pharmaceutical Company Limited* (北京佳誠醫藥有限公司)	1,479	1,479	-
Xizang Linzhibaisheng Pharmaceutical Co., Ltd (西藏林芝百盛藥業有限公司)	3,588	-	-
Type 3 Supplier A	3,300	25	-
Type 1 Supplier B	114	746	-
Xizang Yimingxiya	51	-	-
Lodays Pharmaceutical (Hubai) Company Limited* (朗天藥業(湖北)有限公司)	-	34	-
Others	1,168	830	413
	<u>21,163</u>	<u>22,692</u>	<u>22,003</u>
Total	<u>21,163</u>	<u>22,692</u>	<u>22,003</u>
	(equivalent to approximately HK\$26,082,000)	(equivalent to approximately HK\$28,206,000)	(equivalent to approximately HK\$27,792,000)

Note: The prepayments paid to each supplier included in "Others" contributed to less than 2% of the total prepayments for the two years ended 31 December 2012.

There is no minimum requirement to maintain the prepayment amount with our suppliers.

An increase in sales amount would correspond with an increase in purchase from the suppliers, which would in turn increase prepayments made payable to the suppliers at the same time. For the year ended 31 December 2012, a substantial increase of sales led to an increase in prepayments to certain suppliers. The sales amount of Levocarnitine Injection (左卡尼汀注射液) as supplied by Kaihongxin increased from approximately HK\$20,072,000 for the year ended 31 December 2011 to approximately HK\$52,227,000 for the year ended 31 December 2012, representing an increase of approximately 160.2%. The monthly sales amount of Levocarnitine Injection (左卡尼汀注射液) has been expected to continue to be significant, and thus our Group made a large amount of prepayment to secure the supply.

FINANCIAL INFORMATION

We ceased business relationship with Xizang Linzhibai Sheng Pharmaceutical Co., Ltd* (西藏林芝百盛藥業有限公司) in 2012 due to the changes on its shareholding. The prepayment paid to such supplier was fully returned to us in April 2012. The decrease in the prepayment to Type 3 Supplier A for the year ended 31 December 2012 was mainly due to our use of the prepayment for purchase of raw materials for Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) upon resumption of its production of such product, and we did not make further prepayment considering the current production plan of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) and we will continue to purchase the raw materials from Type 3 Supplier A after the renewal of distribution agreement with Type 1 Supplier A.

For the six months ended 30 June 2013, the increase in prepayment paid to Kaihongxin was due to the increase in the sales amount of Levocarnitine Injection (左卡尼汀注射液), while the prepayment paid to Zhongcheng Huida was generally stable. We had ceased business relationship with Beijing Jiacheng Pharmaceutical Company Limited* (北京佳誠醫藥有限公司), and the deposit and prepayment paid to such supplier were returned to us in March 2013.

In general, the amount of prepayment paid to our suppliers varies with the terms of the distribution contracts entered into between our different suppliers and us, which is determined based on the amount of purchase of goods and netted off against the trade payable of our Group upon the delivery of goods to our Group. However, during the Track Record Period, our Group ceased business relationships with two of our suppliers, namely Beijing Jiacheng Pharmaceutical Company Limited (北京佳誠醫藥有限公司) and Xizang Linzhibai Sheng Pharmaceutical Co., Ltd (西藏林芝百盛藥業有限公司). Each of them subsequently returned the prepayments of approximately HK\$1,479,000 and HK\$3,588,000 to our Group, respectively, upon the cessation of business. Save as disclosed above, our Directors confirmed that our Group has not received any return of prepayments from any of our suppliers during the Track Record Period and as at the Latest Practicable Date.

The following table sets forth an aging analysis of our prepayments as at 31 December 2011, 31 December 2012 and 30 June 2013, respectively:

	As at 31 December 2011		As at 31 December 2012		As at 30 June 2013	
	Amount RMB'000	(%)	Amount RMB'000	(%)	Amount RMB'000	(%)
0-30 days	15,966	75.4	13,169	58.0	14,006	63.6
31-60 days	3,528	16.7	2,940	13.0	2,982	13.6
61-240 days	–	–	–	–	–	–
241-365 days	1,669	7.9	6,583	29.0	5,015	22.8
Over 365 days	–	–	–	–	–	–
Total	21,163	100.0	22,692	100.0	22,003	100.0
	(equivalent to approximately HK\$26,082,000)		(equivalent to approximately HK\$28,206,000)		(equivalent to approximately HK\$27,792,000)	

FINANCIAL INFORMATION

The prepayments for 241-365 days as at 31 December 2011 referred to the prepayment made to Shenyang Meiluo/Type 1 Supplier A, and the prepayments for 241-365 days as at 31 December 2012 referred to the prepayment made to Kaihongxin for a batch of our returned products. As at 30 June 2013, Kaihongxin had fully resumed the supply of the product and the first batch of the product arrived at our warehouse on 24 May 2013. Please refer to the section headed “Business – Our business model - Phase 2 – Procurement of products from our suppliers - Product shortage from our suppliers during Track Record Period” for further details.

As of the Latest Practicable Date, we utilised prepayments to suppliers of approximately HK\$26,108,000, representing approximately 93.9% of outstanding balance amount of our prepayments to suppliers as of 30 June 2013 as our inventory.

Amount due from (to) related parties

The following table sets forth amount due from (to) related parties as of the dates indicated:

	As of 31 December		As of
	2011	2012	30 June
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>2013</i>
			<i>HK\$'000</i>
Amount due from related parties			
Mr. Zhou (<i>Note a</i>)	33	33	33
Mr. Dai (<i>Note a</i>)	24	24	24
Ms. Yang (<i>Note a</i>)	23	23	23
Total	80	80	80
 Amount due to related parties			
Subsidiaries of Town Health			
International (<i>Note b</i>)	(360)	–	–
Yang Qi (<i>Note c</i>)	(1,187)	(554)	–
Total	(1,547)	(554)	–

Notes:

- (a) The amounts were unsecured, non-interest bearing and repayable on demand.
- (b) The amount was due to wholly owned subsidiaries of Town Health International, which represented the amount paid on behalf of the Group, and were unsecured, non-interest bearing and repayable on demand.
- (c) Yang Qi is Ms. Yang's brother and the balance represented the rental expense payable by the Group, which was unsecured, non-interest bearing and repayable on demand.

As confirmed by our Directors, all balances with related parties and a joint venture had been settled as at the Latest Practicable Date.

FINANCIAL INFORMATION

Bank balance and cash/pledge on bank deposits

Bank balances and cash comprise cash held by the Group and short-term bank deposits with an original maturity of three months or less. The deposits carry interest at market rates which range from 0.01% to 1.35%, 0.01% to 1.35% and 0.01% to 1.35% per annum, for each of two years ended 31 December 2011 and 2012 and the six months ended 30 June 2013, respectively.

Pledge on bank deposits in the amount of approximately HK\$1,849,000 represented deposit pledged to a bank to secure general short-term banking facilities granted to the Group. The deposit carried fixed interest rate of 0.01% per annum as at 31 December 2011. The pledged bank deposit had been released during the year ended 31 December 2012.

Trade, bills and other payables

Trade, bills and other payables are comprised of trade payables, bills payables, deposits received, receipt in advance, VAT payables, other tax payables and accruals. The following table sets forth our trade payables as of the dates indicated:

	As of 31 December		As of
	2011	2012	30 June
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>
Trade payables	7,396	7,214	6,854
Bills payables	3,697	–	–
Sub-total	11,093	7,214	6,854
Other payables			
Deposits received	2,280	1,119	568
Receipt in advance	2,473	1,003	1,472
VAT payables	4,919	3,773	6,339
Other tax payables	213	345	498
Accruals	399	1,475	3,525
Subtotal	10,284	7,715	12,402
Total	21,377	14,929	19,256

(i) Trade and bills payables

As of 31 December 2012, our trade and bills payables decreased by approximately 35.0%, to approximately HK\$7,214,000 from approximately HK\$11,093,000 as of 31 December 2011. This decrease was primarily due to the repayment of bill payables under a banking facility granted by the Agricultural Bank of China Limited Hangzhou Jiefang Road branch* (中國農業銀行股份有限公司杭州解放路支行) on 15 May 2011. The bill payables as at 31 December 2011 was for the payment made to Zhongcheng Huida and it was the only time that Zhongcheng Huida accepted the settlement in bill payables instead of cash. Please refer to the section headed “Financial information – Liquidity and capital resources – Bank and other borrowings” for the details of such banking facility.

FINANCIAL INFORMATION

As of 30 June 2013, our trade and bills payables remained stable as compared to the trade payable as at 31 December 2012 and recorded HK\$6,854,000 as at 30 June 2013.

The following table sets forth an aging analysis of trade and bills payables presented based on the received date or issue date, respectively, at the end of the Track Record Period as of the dates indicated:

	As of 31 December				As of 30 June	
	2011		2012		2013	
	Amount		Amount		Amount	
	HK\$'000	(%)	HK\$'000	(%)	HK\$'000	(%)
0 – 30 days	4,350	39.2	1,807	25.0	1,360	19.8
31 – 60 days	12	0.1	4,195	58.2	–	–
61 – 90 days	7	0.1	1,212	16.8	–	–
Over 90 days	6,724	60.6	–	–	5,494	80.2
Total	11,093	100.0	7,214	100.0	6,854	100.0

For those suppliers which grant credit period to us, the average credit period on purchase of goods is 30-60 days. For certain suppliers, our Group is required to make prepayment for the purchase of goods. For the six months ended 30 June 2013, the trade payables over 90 days were payable to Type 1 Supplier A. We subsequently paid approximately HK\$5,297,000 to Type 1 Supplier A as at the Latest Practicable Date.

The following table sets forth the turnover days of our trade and bills payables for the periods indicated:

	Year ended 31 December		Six months
	2011	2012	ended 30 June 2013
Turnover days of trade and bills payables	27	24	20

Note: Turnover days of trade payables is derived by dividing the average of the opening and closing balances of trade payables for the relevant period by total supplier purchase and multiplying this figure by 365 days for a year or 183 days for six months. As of 31 December 2010, we had trade payables of approximately HK\$8,193,000.

Our trade payables turnover days slightly decreased from 27 days for the year ended 31 December 2011 to 24 days and 20 days for the year ended 31 December 2012 and the six months ended 30 June 2013. This was primarily due to (i) a shorter period of time required by our suppliers for payment collection; and (ii) the settlement of bills payables. During the Track Record Period, we had increased the purchases from Baoding Huida and Kaihongxin. These two suppliers did not grant credit period to our Group. The decrease in our trade payable turnover days during the Track Record Period was in line with the aforesaid situation, and was not an implication on the change in our credit profile.

FINANCIAL INFORMATION

As of the Latest Practicable Date, we paid trade and bills payable of approximately HK\$5,681,000, representing approximately 82.9% of our trade and bills payables outstanding balance amount as of 30 June 2013.

Our Directors confirm that there has been no material defaults by our Group in payments of its trade payable during the Track Record Period and up to the Latest Practicable Date.

(ii) Other payables

Other payables comprise deposits received from customers, receipt in advance from customers, VAT payables, other tax payables and accruals. Our other payables were approximately HK\$10,284,000, HK\$7,715,000 and HK\$12,402,000 as of 31 December 2011, 31 December 2012 and 30 June 2013, respectively. The decrease from 31 December 2011 to 31 December 2012 was mainly due to (i) a decrease in deposits received in the amount of approximately HK\$1,161,000 since some Type 2 Distributor Customers terminated business relationships with us due to the expiration of the tender period of certain products; (ii) a decrease in receipt in advance in the amount of approximately HK\$1,470,000 since we reduced the number of Type 3 Distributor Customers, which paid in advance, due to our intended business concentration; and (iii) a decrease in VAT payables in the amount of approximately HK\$1,146,000. The decrease was partially offset by the increase in accruals in the amount of HK\$1,076,000 for the year ended 31 December 2012. The increase from 31 December 2012 to 30 June 2013 was mainly due to (i) an increase in VAT payables in the amount of HK\$2,566,000; and (ii) an increase in accruals in the amount of HK\$2,050,000.

Our Directors confirm that there has been no material defaults by our Group in repayment of its other payables during the Track Record Period and up to the Latest Practicable Date.

Bank and other borrowings

The following table set forth our bank and other borrowings as of the dates indicated:

	As at 31 December		As at
	2011	2012	30 June
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>2013</i>
			<i>HK\$'000</i>
Secured bank loan	–	–	10,736
Unsecured other loan	–	12,000	18,000
	–	12,000	28,736
Total	–	12,000	28,736

The unsecured other loan, which is denominated in HK\$ and carries interest at fixed interest rate of 6% per annum, was raised from E Finance Limited during the year ended 31 December 2012 and repayable in one year. The secured bank loan, which is denominated in RMB and carried interest at fixed interest rate of 6.9% per annum, was raised from Agricultural Bank of China Limited – Hangzhou Jiefang Road branch during the six months ended 30 June 2013 and repayable in one year.

FINANCIAL INFORMATION

The following table illustrates our indebtedness position during the Track Record Period and up to the Latest Practicable Date.

Date of facility available	Status	Lender	Amount of the facility	Interest rate	Unutilised amount available for drawdown as at the Latest Practicable Date
<i>Banking facilities in PRC</i>					
15 May 2011	Released on 3 September 2012	Agricultural Bank of China Limited – Hangzhou Jiefang Road branch	RMB9,500,000 (equivalent to approximately HK\$11,708,000)	N/A (Note 1)	–
10 January 2013	Still valid	Agricultural Bank of China Limited – Hangzhou Jiefang Road branch	RMB8,500,000 (equivalent to approximately HK\$10,566,000)	6.9% per annum	–
<i>Banking facilities in Hong Kong</i>					
22 November 2012	Still valid	E Finance Limited	HK\$18 million	6% per annum	–
9 May 2013	Still valid	A money lending company in Hong Kong	HK\$12,000,000	6% per annum	HK\$12,000,000
17 June 2013	Still valid	A licensed bank in Hong Kong	Overdraft of HK\$5,000,000; and revolving loan of HK\$15,000,000	1.5% per annum over its fixed deposit rate or 1% per annum over HK Inter-Bank Offered Rate, whichever is higher for the overdraft; its HKD Prime Rate per annum for the revolving loan	Overdraft of HK\$4,200,000; and revolving loan of HK\$15,000,000

Note 1: Under such banking facility, our Group used bills payable, which was interest-free, and did not draw down any loan.

FINANCIAL INFORMATION

(i) *Banking facilities in PRC*

On 15 May 2011, the Agricultural Bank of China Limited Hangzhou Jiefang Road branch* (中國農業銀行股份有限公司杭州解放路支行) granted our Group a banking facility, which was personally guaranteed by one of the senior management of our Group, Mr. He and pledged with our Group's self-owned property located at Room 3702, Dikai International Centre, Jianggan District, Hangzhou City, Zhejiang province, the PRC as collateral. The maximum credit amount of such banking facility was RMB9,500,000 (equivalent to approximately HK\$11,708,000) for the period from 17 January 2011 to 16 January 2014. During the Track Record Period, our Group used bills payable, which was interest-free, under such banking facility, and did not draw down any loan. Our Group subsequently released such banking facility on 3 September 2012 in view that (i) one of our suppliers, Type 3 Supplier A, refused the payment by bills payable for settlement of any future purchases, to provide longer credit terms to our Group due to no purchases by our Group in 2011 following the cessation in supply of Sulbenicillin Sodium for Injection (注射用磺苄西林鈉) in January 2011, with its purchase amount of approximately HK\$5.9 million for the year ended 31 December 2010; and (ii) we had no urgent funding needs at that time.

We entered into a maximum amount mortgage contract on 29 November 2012 in the maximum amount of RMB12,510,000 (equivalent to approximately HK\$15,550,000) with Agricultural Bank of China Limited Hangzhou Jiefang Road branch* (中國農業銀行股份有限公司杭州解放路支行) with our self-owned property located at Room 3702, Dikai International Centre, Jianggan District, Hangzhou City, Zhejiang Province, the PRC pledged as collateral. On 10 January 2013, a loan of RMB8,500,000 (equivalent to approximately HK\$10,566,000) was advanced to our Group at the interest rate of 6.9% per annum. Our Group utilised such loan to pay deposit to a supplier to acquire new exclusive national distribution right of one of two products, namely (i) Multiple Electrolytic and Invert Sugar Injection (轉化糖注射液); and (ii) Ozagrel of Sodium for Injection (注射用奧紫格雷鈉).

(ii) *Banking facilities in Hong Kong*

For the year ended 31 December 2012, our Group obtained a loan facility in the maximum amount of HK\$18 million on 22 November 2012. During the Track Record Period, an unsecured loan of HK\$12 million under such loan facility was advanced to our Group. The remaining amount of HK\$6 million was drawn down on 8 February 2013. The unsecured loan, which is denominated in HK\$ and carries interest at fixed interest rate of 6% per annum has been raised from E Finance Limited, an Independent Third Party, which is a licensed money lender in Hong Kong and repayable in one year from the relevant drawdown dates. The proceeds were used to settle Listing expenses of our Group. E Finance Limited is an indirect wholly-owned subsidiary of Jun Yang Solar Power Investments Limited (formerly known as China Gogreen Assets Investment Limited), whose shares are currently listed on the Main Board of the Stock Exchange (Stock code: 397) ("**Jun Yang**"). The ultimate controlling shareholder of our Group, Town Health International, held approximately 18.31% of Jun Yang as at the Latest Practicable Date. At the time when our Group obtained such facility from E Finance Limited, Town Health International only held less than 5% of the issued share capital of Jun Yang. We are advised by a Hong Kong qualified barrister that the loan with E Finance Limited complied with all the relevant laws and regulations in Hong Kong.

FINANCIAL INFORMATION

On 9 May 2013, our Group was granted a loan facility of HK\$12,000,000 by a money lending company in Hong Kong, which is a licensed money lender in Hong Kong and save for such money lender's ultimate beneficial owner being interested approximately 5.13% of the shareholding in one of the Underwriters, an Independent Third Party. The unsecured loan, which is denominated in HK\$ and carries interest at fixed interest rate of 6% per annum will be repayable in six months from the relevant drawdown dates. The unutilised loan facility from a money lending company in Hong Kong was intended to settle the potential payment of deposits and/or prepayment to acquire potential distribution rights in cash when such business opportunities arise in the future.

On 17 June 2013, a licensed bank in Hong Kong provided a banking facility to our Group of an overdraft of HK\$5,000,000 and a revolving loan of HK\$15,000,000 with the interest rate of (a) 1.5% per annum over its fixed deposit rate or 1% per annum over HK Inter-Bank Offered Rate, whichever is higher for the overdraft; and (b) its HKD Prime Rate per annum for the revolving loan. The banking facility is secured by charge to a licensed bank in Hong Kong of a fixed deposit of not less than HK\$5 million or its 110% equivalent in foreign currency by our Group, and corporate guarantee executed by Max Goodrich for unlimited amount.

In respect of the unsecured loan raised from E Finance Limited and another money lender company in Hong Kong, our Group opted to obtain loan from a licensed money lender and/or secured loan from banks in Hong Kong instead of banks in the PRC due to the following reasons:

- (i) **Interest rate:** the interest rate from a licensed money lender in Hong Kong is 6% per annum and the HKD Prime Rate of a licensed bank in Hong Kong is 5.25% as compared to the interest rate from Agricultural Bank of China Limited – Hangzhou Jiefang Road branch that is 6.9% per annum;
- (ii) **Anticipated appreciation in value of RMB:** it would be financially favourable to our Group to acquire the distribution right in PRC (i.e. buying RMB at a lower exchange rate), and repay the loan by using RMB cashflow generated in the future (i.e. selling RMB at a higher exchange rate); and
- (iii) **Fund transferring process:** our Directors do not foresee any material difficulty in transferring the fund raised in Hong Kong to the PRC.

During the Track Record Period and up to the Latest Practicable Date, our Group had not experienced any difficulty in obtaining banking and unsecured loan facilities.

The Directors confirm that there had been no material defaults by our Group in payments of our banking facilities and borrowings during the Track Record Period.

Contingent liabilities

During the Track Record Period, our Group faced a litigation with one of our former Distributor Customer. On 25 June 2012, a former Type 2 Distributor Customer (the “**Plaintiff**”) (which failed to commit the agreed minimum order quantity requirement under our distribution agreement) instituted legal proceedings against Zhejiang Xin Rui Pharmaceutical at Hangzhou Jianggan District People’s Court (杭州市江干區人民法院) (the “**Court**”) claiming, among other things, (i) damages in the total amount of approximately RMB1,018,000 (equivalent to approximately HK\$1,249,000) together with accrued interests

FINANCIAL INFORMATION

thereof; (ii) the deposit paid by the Plaintiff to Zhejiang Xin Rui Pharmaceutical of RMB50,000 (approximately HK\$61,000) together with accrued interests thereof; and (iii) costs of the matter to be borne by the Group, due to the alleged infringement by Zhejiang Xin Rui Pharmaceutical of the exclusive right of a pharmaceutical product granted to that former Type 2 Distributor Customer in contravention of the exclusivity provision under the distribution agreement in question. Please refer to the section headed “Business – Legal proceedings and non-compliance” for details. On 7 July 2013, the Plaintiff withdrew the claim on the alleged infringement from the Court and the Court ordered the costs of the matter to be borne by the Plaintiff. In this connection, given the exclusivity provision contained in the distribution agreement we generally enter into with our Distributor Customers, even if a Distributor Customer fails to satisfy the required minimum order quantity commitment provided under the distribution agreement, we may face claims from time to time initiated by our Distributor Customers for the alleged breach of the terms of the distribution agreements by us despite the fact that we are entitled, under the distribution agreement in question, to exercise our right to forfeit distribution right of the defaulting Distributor Customer and to grant the distribution right to a third party in those markets not yet explored by that defaulting Distributor Customer.

Having sought advice from the legal advisers acting for Zhejiang Xin Rui Pharmaceutical in the aforesaid legal proceedings, our Directors are of the view that the Plaintiff did not have any valid claim against Zhejiang Xiu Rui Pharmaceutical and therefore it is unlikely to have any adverse financial impact on our Group. Therefore, no provision for any losses on litigation was made in the combined financial information for the year ended 31 December 2012 and the six months ended 30 June 2013.

Off-balance sheet commitments and arrangements

As at 31 December 2011, 31 December 2012, 30 June 2013, and the Latest Practicable Date, the Group had no off-balance sheet commitments or arrangements.

INDEBTEDNESS

At the close of business on 31 August 2013, being the date for determining our Group’s indebtedness, our Group had (i) bank borrowing of HK\$10,788,000 which were secured by fixed charges on our Group’s buildings and prepaid lease payments with aggregate carrying values of approximately HK\$12,699,000 and (ii) other unsecured loan of HK\$18,000,000, which remained outstanding.

Apart from intra-group liabilities, as at 31 August 2013, our Group did not have any outstanding loan capital issued or agreed to be issued, bank overdrafts, loans, debt securities, borrowings or other similar indebtedness, liabilities under acceptance (other than normal trade bills) or acceptance credits, debentures, mortgages, charges, finance leases, hire purchase commitments, guarantees or other material contingent liabilities.

Our Directors confirmed that there has been no material adverse change in the indebtedness and contingent liabilities of our Group since 30 June 2013, up to the date of this prospectus. Our Directors also confirmed that our Group has not breached any bank loan covenants or defaulted in repayment of any bank borrowings during the Track Record Period and up to the Latest Practicable Date.

FINANCIAL INFORMATION

DISTRIBUTABLE RESERVES

There was no reserve available for distribution to the Shareholders as at the Latest Practicable Date, as our Company was incorporated on 9 August 2012. It has not carried out any business since the date of incorporation, save for the transactions related to the Reorganisation.

KEY FINANCIAL RATIOS

The following table sets forth a summary of our key financial ratios during the Track Record Period:

Financial Ratios	Formulae	For the year ended 31 December		For the six months ended 30 June	
		2011	2012	2012	2013
Profitability ratios:					
1. Growth					
a. Turnover growth		0.4%	9.6%	23.9%	(6.9%)
b. Net profit growth		85.7%	47.2%	108.7%	(86.7%)
2. Profit margins					
a. Gross margin	a. Gross profit/ Sales x 100%	14.6%	22.3%	23.1%	22.1%
b. Net profit margin before interest expenses and tax	b. Net profit before interest expenses and taxes/Sales x 100%	9.7%	12.7%	18.6%	7.6%
c. Net profit margin	c. Net profit after taxes/Sales x 100%	6.5%	8.8%	12.8%	1.8%
3. Return on equity					
a. Return on equity	a. Net profit/Average Shareholders' equity x 100% (Note 1)	9.4%	12.1%	18.7%	2.2%
b. Return on total assets	b. Net profit/Average total assets x 100% (Note 1)	7.4%	9.8%	15.7%	1.7%
Capital adequacy ratio:					
1. Interest coverage	Profit before interest and tax/interest	82.6	584.8	N/A (Note 2)	7.6

Note 1: The net profit for each of the six months ended 30 June 2012 and 2013 is annualised.

Note 2: For the six months ended 30 June 2012, our Group did not incur any interest expense.

FINANCIAL INFORMATION

				As at 31 December		As at 30 June	
				2011	2012	2013	
Liquidity ratios:							
1.	Liquidity ratios						
	a.	Current ratio	a.	Current assets/ Current liabilities	5.0	5.2	3.1
	b.	Quick ratio	b.	Current assets – Inventories/ Current liabilities	4.4	4.6	2.8
2.	Turnover ratios						
	a.	Inventories turnover days	a.	Average inventories/ Cost of sales x 365 days/183 days	47	42	45
	b.	Receivables turnover days (average collection period)	b.	Average trade and bills receivables/ Sales x 365 days/ 183 days	107	94	95
	c.	Payables turnover days (average payment period)	c.	Average trade and bills payables/total supplier purchase x 365 days/183 days	27	24	20

Capital adequacy ratio:

1.	Gearing ratio ⁽ⁱ⁾	Total debt/Total assets x 100%	1.1%	7.6%	15.0%		
2.	Debt to net worth ratio ⁽ⁱ⁾						
	a.	Debt to equity ratio	a.	Net debt ⁽ⁱⁱ⁾ / (Total assets – Total liabilities) x 100%	Net cash position	Net cash position	Net cash position

(i) Debts are defined to include payables incurred not in the ordinary course of business.

(ii) Net debts are defined to include all borrowings net of cash and cash equivalents.

Gross margin

Our gross margin increased from 14.6% for the year ended 31 December 2011 to 22.3% for the year ended 31 December 2012. The increase in gross profit margin of injection drugs was mainly attributable to the increase in gross profit of (i) Levocarnitine Injection (左卡尼汀注射液); (ii) Ozagrel Sodium for Injection (注射用奥氮格雷钠); and (iii) Mezlocillin Sodium and Sulbactam Sodium for Injection (注射用美洛西林钠舒巴坦钠). The increase in gross profit margin of capsule drugs was mainly attributable to the introduction of Clostridium butyricum Capsule (酪酸梭菌活菌胶囊) in 2012.

Our gross margin decreased from 23.1% for the six months ended 30 June 2012 to 22.1% for the six months ended 30 June 2013. The decrease in gross profit margin was mainly attributable to (i) the decrease in the gross profit margin of injection drugs, as a result of the cessation in the sales of Ozagrel Sodium for Injection (注射用奥氮格雷钠); and (ii) the decrease in the gross profit margin of tablet drugs as a result of the decrease in sales amount of Cefixime Dispersible Tablet (头孢克肟分散片). The decrease in the gross profit margin was

FINANCIAL INFORMATION

partially offset by the increase of the gross profit margin in capsule drugs, as a result of the increase in sales of a product with high gross profit margin, namely, Clostridium butyricum Capsule (酪酸梭菌活菌膠囊).

Net profit margin before interest and tax

Net profit margin before interest and tax increased from 9.7% for the year ended 31 December 2011 to 12.7% for the year ended 31 December 2012. The increase in net profit margin before interest and tax was primarily due to (i) the increase in gross profit margin; and (ii) the increase in imputed interest and adjustment on deposit paid to a supplier, Shenyang Meiluo.

Net profit margin before interest and tax decreased from 18.6% for the six months ended 30 June 2012 to 7.6% for the six months ended 30 June 2013. Such decrease was primarily due to (i) the decrease in gross profit margin; (ii) the increase in the percentage of the Listing expenses over revenue; and (iii) the imputed interest adjustment on deposit paid to suppliers upon initial recognition.

Net profit margin

Net profit margin increased from 6.5% for the year ended 31 December 2011 to 8.8% for the year ended 31 December 2012. The increase in net profit margin was mainly attributable to (i) the increase in net profit margin before interest and tax as mentioned above; (ii) the lower level of finance costs; and (iii) the lower effective tax rate from 31.8% in 2011 to 30.9% in 2012.

Net profit margin decreased from 12.8% for the six months ended 30 June 2012 to 1.8% for the six months ended 30 June 2013. Such decrease in net profit margin was mainly attributable to (i) the decrease in net profit margin before interest and tax as mentioned above; (ii) the higher level of finance costs resulted from the imputed interest adjustment upon initial recognition; and (iii) the higher effective tax rate resulted from the tax effect of the payment of the Listing expenses.

Return on equity

Return on equity increased from 9.4% for the year ended 31 December 2011 to 12.1% for the year ended 31 December 2012. Such increase was mainly due to the increase in net profit for the year ended 31 December 2012 along with the limited usage of liability and borrowings.

Return on equity decreased from 18.7% for the six months ended 30 June 2012 to 2.2% for the six months ended 30 June 2013. Such decrease was mainly due to the decrease in net profit for the six months ended 30 June 2013.

Return on total assets

Return on total assets increased from 7.4% for the year ended 31 December 2011 to 9.8% for the year ended 31 December 2012. Such increase was mainly due to the increase in net profit for the year ended 31 December 2012 along with the limited size of assets and operation scale.

Return on total assets decreased from 15.7% for the six months ended 30 June 2012 to 1.7% for the six months ended 30 June 2013. Such decrease was mainly due to the decrease in net profit for the six months ended 30 June 2013.

FINANCIAL INFORMATION

Interest coverage

Interest coverage increased from 82.6 for the year ended 31 December 2011 to 584.8 for the year ended 31 December 2012 as the interests were limited compared to the profit before interest and tax. Interest coverage was 7.6 for the six months ended 30 June 2013 due to the decrease in net profit before interest and tax for the six months ended 30 June 2013 and the increase in the interest expenses as a result of the imputed interested adjustment on deposit paid to suppliers upon initial recognition and the increase in bank and other borrowings repayable within one year.

Current ratio

Current ratio increased from 5.0 as at 31 December 2011 to 5.2 as at 31 December 2012. Such increase was primarily due to (i) the increase in bank balances and cash, inventory and trade and other receivables due to the increase in operation scale; and (ii) the settlement of payables in an efficient manner.

Current ratio decreased from 5.2 as at 31 December 2012 to 3.1 as at 30 June 2013. Such decrease was primarily due to the increase in bank and other borrowings repayable within one year.

Quick ratio

Quick ratio increased from 4.4 as at 31 December 2011 to 4.6 as at 31 December 2012. Such increase was primarily due to (i) the increase in bank balances and cash and trade and other receivables due to the increase in operation scale; and (ii) the settlement of payables in an efficient manner.

Quick ratio decreased from 4.6 as at 31 December 2012 to 2.8 as at 30 June 2013. Such decrease was primarily due to the increase in bank and other borrowings repayable within one year.

Stock turnover days

Stock turnover days decreased from 47 days for the year ended 31 December 2011 to 42 days for the year ended 31 December 2012, and then slightly increased to 45 days for the six months ended 30 June 2013 as the inventory has been managed efficiently through our inventory management system.

Debtors' turnover days

Debtors' turnover days decreased from 107 days for the year ended 31 December 2011 to 94 days for the year ended 31 December 2012, and then slightly increased to 95 days for the six months ended 30 June 2013. Debtors' turnover days are general in line with the credit period the Group has granted to its customers. Please refer to the section headed "Financial information – Liquidity and capital resources – Trade, bills and other receivables – (i) Trade and bills receivables" for the reasons of changes.

FINANCIAL INFORMATION

Creditors' turnover days

Creditors' turnover days slightly decreased from 27 days for the year ended 31 December 2011 to 24 days for the year ended 31 December 2012, and then decreased to 20 days for the six months ended 30 June 2013. Please refer to the section headed "Financial information – Liquidity and capital resources – Trade, bills and other payables – (i) Trade and bills payables" for the reasons of the decrease.

Gearing ratio

Gearing ratio increased from 1.1% as 31 December 2011 to 7.6% as at 31 December 2012, and then increased to 15.0% as at 30 June 2013. The increase in gearing ratio were attributable to a new raised borrowing of approximately HK\$12 million in 2012, and the increase in bank and other borrowings of approximately HK\$16.7 million in 2013.

Debt to net worth ratio

Our Group maintained the net cash position as at 31 December 2011, 31 December 2012 and 30 June 2013 due to our abundant bank balance and cash.

QUANTITATIVE AND QUALITATIVE INFORMATION ABOUT MARKET RISKS

We are exposed to various types of market risks in the ordinary course of our business, including interest risk, credit risk, and liquidity risk. We manage our exposure to these and other market risks through regular operating and financial activities.

Interest risk

We are exposed to fair value interest rate risk in relation to bank and other borrowings and pledged bank deposits at fixed interest rates and cash flow interest rate risk in relation to bank deposits at floating interest rates.

Our Directors consider that the Group's exposure of the bank balances to cash flow interest rate risk is insignificant as interest bearing bank balances are within short maturity period. Besides, as the fluctuation of market interest rate is not expected to be significant, no sensitivity analysis is prepared.

We currently do not have any interest rate hedging policy in relation to fair value and cash flow interest rate risks. Our Directors monitor the Group's exposure on an ongoing basis and will consider hedging the interest rate, where necessary.

Credit risk

Our credit risk is primarily attributable to trade and other receivables. In order to minimise the credit risk, our management has delegated a team responsible for determination of credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. In addition, we review the recoverable amount of each individual trade debt at each reporting date to ensure that adequate impairment losses are made for irrecoverable amounts. In this regard, our Directors consider that our credit risk is significantly reduced.

FINANCIAL INFORMATION

Our Group has a concentration of credit risk on bank balances as approximately 86%, 92% and 87% of balances are all placed with two banks located in the PRC as at 31 December 2011, 31 December 2012 and 30 June 2013, respectively.

The credit risk on liquid funds is limited because the counterparties are banks with good reputation.

In addition, we have a concentration of credit risks on the outstanding trade and bills receivables and other receivables as 80%, 71% and 67% of the trade and other receivables were due from top five customers in aggregate as at 31 December 2011 and 2012 and 30 June 2013, respectively. Those top five customers were distributors engaged in trading and wholesaling of drugs in Zhejiang province and Shanghai during the Track Record Period with good credit quality. On the other hand, we have a concentration of credit risks on the deposits paid to suppliers as 59%, 80% and 79% of the deposits paid to suppliers were paid to one and three suppliers in aggregate as at 31 December 2011, 31 December 2012 and 30 June 2013, respectively. Such suppliers are also principally engaged in pharmaceutical trading and distribution in the PRC. We have delegated a team responsible for determination of credit limits and monitoring procedures to ensure that follow-up action will be carried out to recover overdue debts.

Other than the above, our Company does not have other significant concentration of credit risk.

Liquidity risk

To encounter the liquidity risk, we monitor and maintain a level of cash and cash equivalent deemed adequate by our management to finance our operations and mitigate the effects of fluctuations in cash flow.

DIVIDEND POLICY

The dividend policy of our Company will be reviewed from time to time by the Board. The dividend that our Directors may recommend or declare in respect of any particular financial year or period will be subject to the factors outlined below as well as any other factors deemed relevant by the Board:

- the level of cash and retained earnings;
- the actual and projected financial performance;
- the projected levels of capital expenditure and other investment plans; and
- restrictions on payment of dividends imposed on our Group by its financing arrangement (if any).

Our Company may declare dividends with the approval of our Shareholders in a general meeting, and subject to our constitutional documents and the Bermuda Companies Act, the amount of such dividend shall not exceed the amount recommended by our Directors. Our Directors may also declare an interim dividend.

FINANCIAL INFORMATION

Dividends are paid by our Company as and when approved by our Shareholders and Directors. Any such dividend payments will be subject to the level of future earnings, cash flow, financial condition and other factors, including such legal or contractual restrictions as may apply from time to time. Past dividends paid are not necessarily indicative of future dividend payments.

During the period from the date of its incorporation on 9 August 2012 to the Latest Practicable Date, our Company had not declared and paid any dividends to the Shareholders.

RECENT DEVELOPMENT

Our Group recorded the sales of approximately HK\$125.9 million for the nine months ended 30 September 2013 and the gross profit margin during the period was similar to that for the six months ended 30 June 2013.

During the Track Record Period and as at the Latest Practicable Date, we identified and acquired 1 product with exclusive national distribution rights and 6 new types of products (including 8 specifications) with exclusive provincial distribution rights but all are subject to the upcoming provincial collective tendering process. For the details of the deposits our Group paid to those suppliers for the newly acquired products with exclusive distribution rights and the sales performance of the newly acquired products with exclusive distribution rights (i) for each of the year ended 31 December 2011 and 2012; (ii) for the six months ended 30 June 2013; and (iii) as at the Latest Practicable Date, please refer to the paragraph headed “Reduction of reliance on our major suppliers” under the sub-section headed “Phase 2 – Procurement of products from our suppliers” under the section headed “Business” of this prospectus.

During the Track Record Period and as at the Latest Practicable Date, our Group has identified 1 product without production permit, namely Fasudil Hydrochloride Injection (鹽酸法舒地爾氯化鈉注射液), where we have entered into a legally binding contract with the relevant supplier of the product and paid RMB1,000,000 as deposit. We will enter the exclusive distribution agreement with such supplier in the event that the pharmaceutical production permit is to be granted before 1 July 2014 or we will terminate such contract and the respective deposit will be returned to our Group accordingly.

For further information, please refer to the paragraph headed “Reduction of the reliance on our major suppliers” under the “Business” section of this prospectus.

FINANCIAL INFORMATION

PROPERTY INTEREST AND PROPERTY VALUATION

Ascent Partners Valuation Service Limited, an independent property valuer, has valued the property interests of our Group, comprising the operations, as at 31 August 2013. Text of its letters, summary of valuation and valuation certificates issued by Ascent Partners Valuation Service Limited is included in “Appendix III – Property Valuation” to this prospectus.

The table below sets forth the reconciliation of the aggregate amount of net book value of our Group’s property interests from our combined financial information as of 30 June 2013 to the valuation of property interests as of 31 August 2013:

	<i>HK\$’000</i>
Valuation of properties of RMB12,400,000 as of 31 August 2013 as set out in Appendix III of this prospectus (<i>Note 1</i>)	<u>15,662</u>
Prepaid lease payments (<i>Note 2</i>)	8,756
Property, plant and equipment (<i>Note 2</i>)	<u>3,994</u>
Net book value of property interests of our Group as at 30 June 2013	12,750
Less: Depreciation and amortisation for the period of time from 30 June 2013 to 31 August 2013	<u>51</u>
Net book value of property interests of our Group as at 31 August 2013	12,699
Valuation surplus	<u>2,963</u>

Notes:

- (1) The valuation includes the market value of the property no.2 assuming that the relevant title certificates have been obtained and the property is freely disposed of in the market.
- (2) The net book values of buildings and prepaid lease payments are extracted from the accountants’ report set out in Appendix I to this prospectus.

DISCLOSURE UNDER CHAPTER 17 OF THE GEM LISTING RULES

Our Directors have confirmed that, as at the Latest Practicable Date, they were not aware of any circumstances which would give rise to a disclosure requirement under Rules 17.15 to 17.21 of the GEM Listing Rules.

NO MATERIAL ADVERSE CHANGES

Our Directors have confirmed that there has been no material adverse changes in the financial or trading position of our Group since 30 June 2013 (being the date to which the latest combined financial statements of our Group were prepared as set in the “Appendix I – Accountants’ Report” to this prospectus) and there is no event or event since 30 June 2013 which would materially affect the information as shown in the Accountants’ Report, in each case except as otherwise disclosed in this prospectus.